var title_f22_31_23024="Barretts esophagectomy Gross";
var content_f22_31_23024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Esophagectomy specimen in a patient found to have high-grade dysplasia during endoscopic surveillance. Salmon-colored Barrett's mucosa has replaced the squamous mucosa circumferentially. Scattered erosions are visible (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23024=[""].join("\n");
var outline_f22_31_23024=null;
var title_f22_31_23025="Esoph cancer autofluorescence";
var content_f22_31_23025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Autofluorescence image of esophageal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White light endoscopic view of the distal esophagus in a patient with Barrett's esophagus (left panel). Corresponding autofluorescence image (right panel) showing a blue/purple color (right side) suggestive of early neoplasia, which was confirmed by biopsy. This lesion was first detected with autofluorescence and only retrospectively by white light imaging.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kara MA, Peters FP, Ten Kate FJ, et al. Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett's esophagus. Gastrointest Endosc 2005; 61:679. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23025=[""].join("\n");
var outline_f22_31_23025=null;
var title_f22_31_23026="Patient information: Neck pain (The Basics)";
var content_f22_31_23026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15793\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/46/15074\">",
"         Anatomy of the neck",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/7/36978\">",
"         Patient information: Low back pain in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/0/15363\">",
"         Patient information: Neck fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/45/17106\">",
"         Patient information: Whiplash (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/35/27188\">",
"         Patient information: Neck pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Neck pain (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/neck-pain-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13397283\">",
"      <span class=\"h1\">",
"       What can cause neck pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Neck pain happens when there is a problem with or injury to any of the parts (&ldquo;structures&rdquo;) in the neck (",
"      <a class=\"graphic graphic_figure graphicRef72120 \" href=\"UTD.htm?14/46/15074\">",
"       figure 1",
"      </a>",
"      ). The structures in the neck include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Bones &ndash; The neck has 7 bones that are stacked on top of each other. These bones make up the top part of the spine and are called the &ldquo;cervical vertebrae.&rdquo; Neck pain can happen when the bones get worn down or develop abnormal growths (called &ldquo;bone spurs&rdquo;).",
"       </li>",
"       <li>",
"        Ligaments &ndash; Ligaments are strong tissues that connect bones to other bones. Ligament damage can happen when the neck moves back and forth suddenly (called &ldquo;whiplash&rdquo;), such as in a car accident.",
"       </li>",
"       <li>",
"        Discs &ndash; Discs are cushions that sit between the bones. When the discs change shape or move out of position, people can have symptoms.",
"       </li>",
"       <li>",
"        Muscles &ndash; Muscles hold the head up and make the neck move. Neck pain can be caused by muscle strain or tension, such as from poor posture or stress.",
"       </li>",
"       <li>",
"        Nerves &ndash; A bundle of nerves (called the spinal cord) travels down the middle of the spine. Nerves branch off from the spinal cord to all parts of the body. People can have symptoms if their nerves are irritated or pushed on by nearby bones or discs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397290\">",
"      <span class=\"h1\">",
"       What symptoms can people with neck pain have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People can have different symptoms that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain, stiffness, or tightness in the neck, shoulders, upper back, or arms",
"       </li>",
"       <li>",
"        Headaches",
"       </li>",
"       <li>",
"        Neck weakness",
"       </li>",
"       <li>",
"        Being unable to move or turn the neck",
"       </li>",
"       <li>",
"        Pain when turning or tilting the head",
"       </li>",
"       <li>",
"        Numbness or strange feelings (such as pins and needles) in the shoulders or arms",
"       </li>",
"       <li>",
"        Trouble walking or moving the legs",
"       </li>",
"       <li>",
"        Having no control over the bladder or bowels",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397297\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should see a doctor or nurse if you have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A severe injury to your head or neck",
"       </li>",
"       <li>",
"        Severe pain",
"       </li>",
"       <li>",
"        No control over your bladder or bowels",
"       </li>",
"       <li>",
"        Numbness or weakness in your arms or legs",
"       </li>",
"       <li>",
"        Pain that doesn&rsquo;t get better after you treat it at home for 1 week",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397304\">",
"      <span class=\"h1\">",
"       Do I need to have tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people do not need any tests. Your doctor or nurse will do an exam. He or she will feel your muscles and check how your head and neck move.",
"     </p>",
"     <p>",
"      But some people might need tests. Tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        X-ray, CT scan, MRI scan, or other imaging tests &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        Muscle or nerve tests to see if the muscles and nerves work normally",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397311\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To reduce your symptoms, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take a pain-relieving medicine",
"       </li>",
"       <li>",
"        Massage the muscles that are tight or tense",
"       </li>",
"       <li>",
"        Put ice on the area to reduce pain &ndash; You can rub ice on the area for 5 to 7 minutes. Or you can put a frozen bag of peas or a cold gel pack on the area for 20 minutes at a time, a few times a day.",
"       </li>",
"       <li>",
"        Put heat on the area to reduce pain and stiffness &ndash; Take a hot shower or hot bath, or put a hot towel on the area. Don&rsquo;t use heat for more than 20 minutes at a time. Don&rsquo;t use anything too hot that could burn your skin.",
"       </li>",
"       <li>",
"        Do neck exercises &ndash; Different exercises can stretch the neck, shoulder, and back muscles and help make them stronger. Ask your doctor or nurse if you should do exercises, and which ones can help your symptoms.",
"       </li>",
"       <li>",
"        Reduce stress &ndash; Stress can make pain worse and prevent symptoms from getting better. Try to reduce your stress. You can ask your doctor or nurse about exercises that can help you relax.",
"       </li>",
"       <li>",
"        Watch your posture &ndash; Try to keep your neck straight in line with your body and avoid activities that involve a lot of neck movement. When you sleep, keep your head and neck in line with your body. Try to avoid sleeping on your stomach with your head turned to one side.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397318\">",
"      <span class=\"h1\">",
"       What other treatments might I have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse can use other treatments if your neck pain doesn&rsquo;t improve after you treat it at home. For example, he or she might suggest that you see an exercise expert, called a physical therapist. Or your doctor can inject a numbing medicine into your neck.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397325\">",
"      <span class=\"h1\">",
"       Can neck pain be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help prevent neck pain, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use good posture &ndash; Hold your head up and keep your shoulders down.",
"       </li>",
"       <li>",
"        Avoid sitting in the same position for too long",
"       </li>",
"       <li>",
"        Avoid doing work above your head for too long",
"       </li>",
"       <li>",
"        Avoid putting weight or pressure on your upper back",
"       </li>",
"       <li>",
"        Keep your neck in line with the rest of your body when you sleep",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13397332\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=see_link\">",
"       Patient information: Low back pain in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/45/17106?source=see_link\">",
"       Patient information: Whiplash (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=see_link\">",
"       Patient information: Neck pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/0/15363?source=see_link\">",
"       Patient information: Neck fracture (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/31/23026?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15793 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23026=[""].join("\n");
var outline_f22_31_23026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397283\">",
"      What can cause neck pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397290\">",
"      What symptoms can people with neck pain have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397297\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397304\">",
"      Do I need to have tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397311\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397318\">",
"      What other treatments might I have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397325\">",
"      Can neck pain be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13397332\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15793\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/46/15074\">",
"      Anatomy of the neck",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=related_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/0/15363?source=related_link\">",
"      Patient information: Neck fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=related_link\">",
"      Patient information: Neck pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/45/17106?source=related_link\">",
"      Patient information: Whiplash (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_31_23027="Pralidoxime: Patient drug information";
var content_f22_31_23027=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pralidoxime: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16517?source=see_link\">",
"     see \"Pralidoxime: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/15/12532?source=see_link\">",
"     see \"Pralidoxime: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Protopam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to avoid side effects from nerve gas or chemicals that kill insects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702775",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pralidoxime or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10927 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-7288C09AE7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23027=[""].join("\n");
var outline_f22_31_23027=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212244\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029565\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029564\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029568\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029569\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029571\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029567\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029572\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029573\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16517?source=related_link\">",
"      Pralidoxime: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/15/12532?source=related_link\">",
"      Pralidoxime: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_31_23028="Prolapsed internal hemorrhoids";
var content_f22_31_23028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75759%7EGAST%2F72916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75759%7EGAST%2F72916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prolapsed internal hemorrhoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 280px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Internal hemorrhoids which have prolapsed outside of the anal canal and are visibly bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the American Society of Colon and Rectal Surgeons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thrombosed external hemorrhoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph shows a swollen external hemorrhoid (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission of the American Society of Colon and Rectal Surgeons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23028=[""].join("\n");
var outline_f22_31_23028=null;
var title_f22_31_23029="Isoproterenol: Drug information";
var content_f22_31_23029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isoproterenol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/46/8932?source=see_link\">",
"    see \"Isoproterenol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/25/38291?source=see_link\">",
"    see \"Isoproterenol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Isuprel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta",
"      <sub>",
"       1",
"      </sub>",
"      /Beta",
"      <sub>",
"       2",
"      </sub>",
"      Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients may exhibit dose-dependent vasodilation due to unopposed beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonism elicited by isoproterenol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bradyarrhythmias, AV nodal block, or refractory torsade de pointes:",
"     </b>",
"     Continuous I.V. infusion: Usual range: 2-10 mcg/minute; titrate to patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Brugada syndrome with electrical storm (unlabeled use):",
"     </b>",
"     I.V. bolus: Initial: 1-2 mcg, followed by a continuous infusion of 0.15-0.3 mcg/minute for 1 day; may repeat sequence if ventricular tachycardia/fibrillation recurs (Watanabe, 2006; Zipes, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tilt table testing for syncope (Benditt, 1996; Brignole, 2004):",
"     </b>",
"     Continuous I.V infusion: Initial: 1 mcg/minute; increase as necessary based on response; maximum dose: 5 mcg/minute.",
"     <b>",
"      Note:",
"     </b>",
"     Timing of initiation and dose adjustment during test may be institution-specific.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F184892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/25/38291?source=see_link\">",
"      see \"Isoproterenol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients may exhibit dose-dependent vasodilation due to unopposed beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonism elicited by isoproterenol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bradyarrhythmias, AV nodal block, or refractory torsade de pointes:",
"     </b>",
"     Continuous I.V. infusion: Usual range: 0.05-2 mcg/",
"     <b>",
"      kg",
"     </b>",
"     /minute; titrate to patient response.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isuprel&reg;: 0.2 mg/mL (1 mL, 5 mL) [contains sodium metabisulfite; 1:5000]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F184853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. infusion administration requires the use of an infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg in 100 mL (10",
"     <b>",
"      mcg",
"     </b>",
"     /mL), 1 mg in 500 mL (2",
"     <b>",
"      mcg",
"     </b>",
"     /mL),",
"     <b>",
"      or",
"     </b>",
"     4 mg in 250 mL (16",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     20",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F184917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose 5%, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      2.5",
"     </sub>",
"     W,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with sodium bicarbonate 5% and alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, atracurium, bivalirudin, caffeine citrate, cisatracurium, dexmedetomidine, famotidine, fenoldopam, heparin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, inamrinone, levofloxacin, milrinone, nitroprusside, pancuronium, potassium chloride, propofol, remifentanil, tacrolimus, vecuronium, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Manufacturer&rsquo;s labeled indications (see",
"     <b>",
"      \"Note\"",
"     </b>",
"     ): Mild or transient episodes of heart block that do not require electric shock or pacemaker therapy; serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation); cardiac arrest until electric shock or pacemaker therapy is available; bronchospasm during anesthesia; adjunct to fluid and electrolyte replacement therapy and other drugs and procedures in the treatment of hypovolemic or septic shock and low cardiac output states (eg, decompensated heart failure, cardiogenic shock)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The use of isoproterenol in advanced cardiac life support (ACLS) has largely been supplanted by the use of other adrenergic agents (eg, epinephrine and dopamine). The use of isoproterenol for bronchospasm during anesthesia and cardiogenic, hypovolemic, or septic shock is no longer recommended. See",
"     <i>",
"      Unlabeled/Investigational Use",
"     </i>",
"     for more appropriate, yet unlabeled, uses.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F184907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pharmacologic overdrive pacing for refractory torsade de pointes; pharmacologic provocation during tilt table testing for syncope; temporary control of bradycardia in denervated heart transplant patients unresponsive to atropine; ventricular arrhythmias due to AV nodal block; beta-blocker overdose; electrical storm associated with Brugada syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F184919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Isuprel&reg; may be confused with Disophrol&reg;, Isordil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F184908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, flushing, hyper-/hypotension, pallor, palpitation, paradoxical bradycardia (with tilt table testing), premature ventricular beats, Stokes-Adams attacks, tachyarrhythmia, ventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, nervousness, restlessness, Stokes-Adams seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia, serum glucose increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angina, pre-existing ventricular arrhythmias, tachyarrhythmias; cardiac glycoside intoxication",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, coronary artery disease); may increase myocardial oxygen demand resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may transiently increase blood glucose levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Distributive shock: Avoid use in patients with distributive shock; may reduce systemic vascular resistance (SVR) further resulting in hemodynamic compromise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism; may induce thyroid storm in susceptible individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Contains sulfites; may cause allergic reaction in susceptible individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Use with extreme caution; not currently a treatment of choice. Excessive or prolonged use may result in decreased effectiveness.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of Isoproterenol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Isoproterenol may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F184867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid ephedra, yohimbe (may cause CNS stimulation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7732005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Adequate studies have not been conducted in pregnant women; use during pregnancy when the potential benefit to the mother outweighs the possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F184877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isuprel Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg/mL (1 mL): $47.88",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F184848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG, heart rate, respiratory rate, arterial blood gas, arterial blood pressure, CVP; serum glucose, serum potassium, serum magnesium",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aleudrina (ES);",
"     </li>",
"     <li>",
"      Antasthmin (AT);",
"     </li>",
"     <li>",
"      Asmadren (NO);",
"     </li>",
"     <li>",
"      Bellasthman Medihaler (DE);",
"     </li>",
"     <li>",
"      Dyspnoesan (NL);",
"     </li>",
"     <li>",
"      Erydin (DK);",
"     </li>",
"     <li>",
"      Euspiran (CZ);",
"     </li>",
"     <li>",
"      Ingelan (AT, DE);",
"     </li>",
"     <li>",
"      Isolin (IN);",
"     </li>",
"     <li>",
"      Isomel (IE);",
"     </li>",
"     <li>",
"      Isomenyl (JP);",
"     </li>",
"     <li>",
"      Isoprenalin (NO, SE);",
"     </li>",
"     <li>",
"      Isoprenalina Cloridrato (IT);",
"     </li>",
"     <li>",
"      Isoprenalinhydrochlorid-Braun (LU);",
"     </li>",
"     <li>",
"      Isuprel (HU, LU);",
"     </li>",
"     <li>",
"      Isuprel HCl (BE, FR, HK, KP, TH);",
"     </li>",
"     <li>",
"      Isuprel Inj (AU, NZ);",
"     </li>",
"     <li>",
"      Isuprel Mistometer (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Kattwilon N (DE);",
"     </li>",
"     <li>",
"      Medihaler-Iso (GB, LU, NL, PT);",
"     </li>",
"     <li>",
"      Min-I-Jet Isoprenaline (GB);",
"     </li>",
"     <li>",
"      Novodrin (DE);",
"     </li>",
"     <li>",
"      Proterenal (AR);",
"     </li>",
"     <li>",
"      Proternol L (TW);",
"     </li>",
"     <li>",
"      Saventrine (FI, GB, GR, IE, SG);",
"     </li>",
"     <li>",
"      Sedansol Iso (JP);",
"     </li>",
"     <li>",
"      Sooner (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F184838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors resulting in relaxation of bronchial, GI, and uterine smooth muscle, increased heart rate and contractility, vasodilation of peripheral vasculature",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F184855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.V.: 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via conjugation in many tissues including hepatic and pulmonary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.5-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as sulfate conjugates)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Almquist A, Goldenberg IF, Milstein S, et al, &ldquo;Provocation of Bradycardia and Hypotension by Isoproterenol and Upright Posture in Patients With Unexplained Syncope,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1989, 320(6):346-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23029/abstract-text/2913492/pubmed\" id=\"2913492\" target=\"_blank\">",
"        2913492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benditt DG, Ferguson DW, Grubb BP, et al, &ldquo;Tilt Table Testing for Assessing Syncope. American College of Cardiology,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1996, 28(1):263-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23029/abstract-text/8752825/pubmed\" id=\"8752825\" target=\"_blank\">",
"        8752825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brignole M, Alboni P, Benditt DG, et al, &ldquo;Guidelines on Management (Diagnosis and Treatment) of Syncope &ndash; Update 2004,&rdquo;",
"      <i>",
"       Europace",
"      </i>",
"      , 2004, 6(6):467-537.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23029/abstract-text/15519256/pubmed\" id=\"15519256\" target=\"_blank\">",
"        15519256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23029/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keren A, Tzivoni D, Gavish D, et al, \"Etiology, Warning Signs and Therapy of Torsade de Pointes. A Study of 10 Patients,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 1981, 64(6):1167-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23029/abstract-text/7296791/pubmed\" id=\"7296791\" target=\"_blank\">",
"        7296791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watanabe A, Fukushima Kusano K, Morita H, et al, \"Low-Dose Isoproterenol for Repetitive Ventricular Arrhythmia in Patients With Brugada Syndrome,\"",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2006, 27(13):1579-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23029/abstract-text/16760208/pubmed\" id=\"16760208\" target=\"_blank\">",
"        16760208",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zipes DP, Camm AJ, Borggrefe M, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(5):247-346.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23029/abstract-text/16949478/pubmed\" id=\"16949478\" target=\"_blank\">",
"        16949478",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8578 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23029=[""].join("\n");
var outline_f22_31_23029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184870\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184910\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184872\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184892\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184873\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160042\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160043\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184850\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184835\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184853\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472666\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472667\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184917\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184851\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184907\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184919\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184908\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184856\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184839\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299548\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184844\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184867\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184846\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7732005\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184877\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323236\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184848\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038663\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184838\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184855\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8578\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8578|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/46/8932?source=related_link\">",
"      Isoproterenol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/25/38291?source=related_link\">",
"      Isoproterenol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_31_23030="Investigational treatments of chronic hepatitis B virus infection";
var content_f22_31_23030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Investigational treatments of chronic hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23030/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23030/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23030/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23030/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23030/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23030/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/31/23030/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main aim of treatment for chronic hepatitis B is to suppress HBV replication before there is irreversible liver damage. This topic review will discuss experimental treatments of chronic hepatitis B. A general approach to patients with hepatitis B (including other treatment options) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIVIRAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of antiviral agents for the treatment of chronic hepatitis B continue to be evaluated in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Emtricitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     Emtricitabine",
"    </a>",
"    (FTC) is a nucleoside analogue that is structurally similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and has potent antiviral activity against HBV and HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The largest published study included 248 patients with chronic HBV (both HBeAg positive and negative) who had never received prior treatment with an",
"    <span class=\"nowrap\">",
"     nucleoside/tide",
"    </span>",
"    analogue and were randomly assigned to emtricitabine or placebo for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/2\">",
"     2",
"    </a>",
"    ]. Histologic improvement (defined as a 2-point reduction in the Knodell necroinflammatory score) was observed significantly more often in the active treatment group (62 versus 25 percent). Loss of detectable HBV DNA also occurred significantly more often with emtricitabine (54 versus 2 percent). However, HBV mutants with resistance to emtricitabine were observed in 13 percent of patients while HBeAg seroconversion was not significantly different than placebo.",
"   </p>",
"   <p>",
"    Although studies comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (or other oral agents) have not been performed, these data suggest that emtricitabine (200 mg daily) does not offer a clinically meaningful advantage since rates of HBV DNA loss, HBeAg seroconversion, histologic improvement and the development of resistant mutations are similar. In addition, mutants that are resistant to emtricitabine are also resistant to lamivudine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    and less sensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    . Thus, the role of emtricitabine monotherapy in the treatment of chronic hepatitis B is limited. Studies on combination therapy are in progress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=see_link\">",
"     \"Combination therapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Drugs no longer under development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several drugs showed initial promise but are no longer under development for a variety of reasons. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , val-d-cytosine (LdC), valtorcitabine, LB80380, alamifovir, and pradefovir. Clevudine was approved in Korea but subsequently withdrawn due to postmarketing reports of myopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NOVEL ANTIVIRAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several innovative antiviral approaches have been evaluated in in vitro and in animal models of chronic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/3\">",
"     3",
"    </a>",
"    ]. It is at present unknown if these approaches will have clinical utility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Selective targeting of antiviral agents to the liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategies involving conjugation of antiviral agents to ligands that are selectively taken up by the liver or the creation of prodrugs that require activation in the liver may permit these drugs to be used in lower doses, while possibly increasing efficacy and decreasing systemic adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antisense approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcription and translation of HBV DNA and HBV RNA can be prevented by antisense molecules or ribozymes that are complementary to the DNA or RNA templates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/7\">",
"     7",
"    </a>",
"    ]. These molecules can be delivered by the administration of preformed molecules or vector DNA. The advantage of this approach is that specific targets can be selected. In addition, the risk of drug-resistant mutants can be reduced by targeting multiple sites in the viral DNA or RNA or by targeting regulatory sequences that would not tolerate mutations.",
"   </p>",
"   <p>",
"    In vitro studies have confirmed that this approach is feasible. The major impediments to the clinical use of antisense treatment include rapid degradation of the antisense molecules by nucleases in vivo, lack of an efficient delivery system into the target cells, and hindrance of access to target DNA or RNA sequences by secondary structure. Several pilot studies have demonstrated the feasibility of delivery of antisense molecules to DHBV-infected ducks and the efficacy of these molecules in inhibiting DHBV replication and viral protein expression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/8\">",
"     8",
"    </a>",
"    ]. Pilot studies in mice showed that ribozymes can be delivered to the liver in sufficient concentrations for antiviral effect [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/7\">",
"     7",
"    </a>",
"    ]. An in vitro study suggested that an anti-HBV ribozyme (HepBzyme) which cleaved HBV RNA in the S region decreased HBV replication as well as HBsAg expression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, combination of HepBzyme and interferon or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    appeared to have additive antiviral effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     RNA interference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short strands of RNA (siRNAs) can be created that cause inhibition of hepatitis B virus expression and replication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In vitro and animal studies have suggested a potential therapeutic role for these molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/10,12-16\">",
"     10,12-16",
"    </a>",
"    ]. Human studies are planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Non-HBV-specific immunomodulatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-HBV specific immunomodulation with thymosin has been studied in patients with chronic HBV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Thymosin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymic-derived peptides can stimulate T cell function. Treatment is usually well tolerated but data on efficacy are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/17-22\">",
"     17-22",
"    </a>",
"    ]. A meta-analysis that included five controlled trials with a total of 353 patients concluded that patients treated with thymosin were significantly more likely than controls to have a virologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/22\">",
"     22",
"    </a>",
"    ]. The maximal rate of response was not seen until 12 months after discontinuing therapy (odds ratio 1.67, 95% CI 0.83 to 3.37). In one of the largest and most recent controlled trials, for example, 98 patients were randomly assigned to thymosin alpha 1 (1.6 mg subcutaneously twice per week) for 26 or 52 weeks or no specific treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/19\">",
"     19",
"    </a>",
"    ]. Clearance of HBV DNA and HBeAg at 18 months were observed significantly more often in the two groups that received active treatment (41 and 27 versus 9 percent, respectively). Ongoing studies are evaluating combination therapy with other antiviral agents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Thymosin alpha is approved for treatment of HBV in several countries, mainly in Asia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     HBV-specific immunomodulatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past few years, several HBV-specific immunomodulatory therapies have been developed, some of which have shown promise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     S and pre-S antigen vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that incorporation of pre-S (pre-surface) antigens into hepatitis B vaccines could increase the immunogenicity of the vaccine. In one study, 170 patients were randomized to receive GenHevac",
"    <span class=\"nowrap\">",
"     (preS2/S",
"    </span>",
"    antigen containing vaccine), Recombivax (S antigen containing vaccine), or no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/25\">",
"     25",
"    </a>",
"    ]. Available data in 40 patients showed that clearance of HBV DNA occurred in 5 of 17 patients who received GenHevac B, 2 of 10 patients who received Recombivax, and in 1 of 13 controls. Although GenHevac appeared to be associated with a higher rate of antiviral response, the high drop out rate and the subsequent use of interferon therapy at the end of the vaccination schedule make it difficult to interpret the results of this study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=see_link&amp;anchor=H2#H2\">",
"     \"Characteristics of the hepatitis B virus and pathogenesis of infection\", section on 'Characteristics of the virus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     DNA vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination with plasmid DNA can stimulate both B and T cell responses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/26\">",
"     26",
"    </a>",
"    ]. Studies in mice have shown that vaccination with plasmids that contain HBV surface gene can induce an anti-HBs response. DNA vaccination can also decrease the production of HBsAg in transgenic mice that express the HBV surface gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/27\">",
"     27",
"    </a>",
"    ]. It remains to be determined whether DNA vaccination can induce anti-HBs production and viral clearance in patients with chronic HBV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     T cell vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic HBV infection have an impaired cytotoxic T lymphocyte (CTL) response to HBV antigens, resulting in ineffective virus clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/28\">",
"     28",
"    </a>",
"    ]. A phase II study showed that the CTL response can be stimulated in patients with chronic HBV infection by inoculation with a vaccine that contained an HLA-restricted HBcAg CTL epitope; however, the antiviral effect was weak [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Adoptive immunity transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization of bone marrow transplant donors with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    can induce anti-HBs antibody production in recipients through adoptive immune transfer. In addition, bone marrow transplantation from donors who are anti-HBs and anti-HBc positive has been associated with clearance of HBV in recipients with chronic HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/30\">",
"     30",
"    </a>",
"    ]. This occurrence appears to be related to the transfer of hepatitis B core antigen-reactive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone marrow transplantation is associated with significant morbidity and mortality, and is therefore not a viable option for the treatment of chronic hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Alpha-glucosidase inhibitor derivatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucosidases are important cellular enzymes in glycoprotein biosynthesis. They mediate the proper folding of cellular as well as viral structural proteins. As a result, inhibitors of glucosidases have become targets for antiviral therapy. Two derivatives (N-nonyl-DNJ and N-nonyl-DGJ) of N-butyl-DNJ, a glucosidase inhibitor, were associated with a 9- and 15-fold drop in secreted HBV DNA in an in vitro model [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/32\">",
"     32",
"    </a>",
"    ]. These compounds did not interfere with glucosidase activity and had no evidence of cytotoxicity. Whether these agents will be safe and effective in vivo remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase I trial demonstrated that monoclonal antibodies directed against different epitopes of hepatitis B surface antigen could decrease HBsAg and HBV DNA levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/33\">",
"     33",
"    </a>",
"    ]. The long-term benefit of such therapy given alone or in combination with other antiviral approaches remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     THERAPY AIMED AT IMPROVING FIBROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A novel approach in the treatment of liver disease involves therapy aimed at reducing fibrosis progression or improving existing fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=see_link\">",
"     \"Emerging therapies for hepatic fibrosis\"",
"    </a>",
"    .) Although antiviral therapy has the potential to improve fibrosis, alternative strategies involve administration of agents designed to interfere directly with hepatic fibrosis while not necessarily exerting an antiviral effect.",
"   </p>",
"   <p>",
"    Interferon gamma (IFN-gamma) is a cytokine secreted primarily by T-cells (CD4+ T cells, CD8+ T cells, and natural killer cells). Animal models suggest that IFN-gamma can inhibit the proliferation of hepatic stellate cells and reduce collagen synthesis providing a rationale for studies in patients with chronic liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=see_link\">",
"     \"Emerging therapies for hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest study in HBV involved 99 patients with HBsAg positive chronic HBV and fibrosis who were randomly assigned to active treatment for nine months or to serve as untreated controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23030/abstract/34\">",
"     34",
"    </a>",
"    ]. Hepatic fibrosis scores improved significantly in the group randomized to active treatment. No serious adverse effects were reported, although side-effects included fever, headache, musculoskeletal pain, and a decrease in the white blood cell and platelets count, leading to discontinuation of treatment in five patients. Further studies with longer follow-up are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       \"Patient information: Hepatitis B (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       \"Patient information: Hepatitis B (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92258100\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novel approaches to treatment of chronic HBV continue to be developed. These include novel antiviral agents, vaccine strategies, and drugs aimed at improving fibrosis.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/1\">",
"      Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005; 43:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/2\">",
"      Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006; 166:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/3\">",
"      von Weizs&auml;cker F, Wieland S, K&ouml;ck J, et al. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology 1997; 26:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/4\">",
"      Erion MD, van Poelje PD, Mackenna DA, et al. Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther 2005; 312:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/5\">",
"      Torrani Cerenzia M, Fiume L, De Bernardi Venon W, et al. Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. Hepatology 1996; 23:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/6\">",
"      Korba BA, Xie H, Wright KN, et al. Liver-targeted antiviral nucleosides: enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo. Hepatology 1996; 23:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/7\">",
"      Lee PA, Blatt LM, Blanchard KS, et al. Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology 2000; 32:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/8\">",
"      Offensperger WB, Blum HE, Gerok W. Therapy of hepadnavirus infection using antisense oligonucleotides. Intervirology 1995; 38:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/9\">",
"      Morrissey DV, Blanchard K, Shaw L, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005; 41:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/10\">",
"      Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 2003; 37:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/11\">",
"      Davidson BL. Hepatic diseases--hitting the target with inhibitory RNAs. N Engl J Med 2003; 349:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/12\">",
"      Hamasaki K, Nakao K, Matsumoto K, et al. Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett 2003; 543:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/13\">",
"      Ying C, De Clercq E, Neyts J. Selective inhibition of hepatitis B virus replication by RNA interference. Biochem Biophys Res Commun 2003; 309:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/14\">",
"      Konishi M, Wu CH, Wu GY. Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. Hepatology 2003; 38:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/15\">",
"      Chen Y, Du D, Wu J, et al. Inhibition of hepatitis B virus replication by stably expressed shRNA. Biochem Biophys Res Commun 2003; 311:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/16\">",
"      Giladi H, Ketzinel-Gilad M, Rivkin L, et al. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003; 8:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/17\">",
"      Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991; 14:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/18\">",
"      Andreone P, Cursaro C, Gramenzi A, et al. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B. Hepatology 1996; 24:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/19\">",
"      Chien RN, Liaw YF, Chen TC, et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998; 27:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/20\">",
"      Mutchnick MG, Lindsay KL, Schiff ER, et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat 1999; 6:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/21\">",
"      Fattovich G, Giustina G, Alberti A, et al. A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. J Hepatol 1994; 21:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/22\">",
"      Chan HL, Tang JL, Tam W, Sung JJ. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther 2001; 15:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/23\">",
"      Lau GK, Nanji A, Hou J, et al. Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J Viral Hepat 2002; 9:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/24\">",
"      Saruc M, Yuceyar H, Kucukmetin N, et al. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey. Hepatogastroenterology 2002; 49:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/25\">",
"      Couillin I, Pol S, Mancini M, et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999; 180:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/26\">",
"      Whalen RG, Leclerc C, D&eacute;riaud E, et al. DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Ann N Y Acad Sci 1995; 772:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/27\">",
"      Mancini M, Hadchouel M, Davis HL, et al. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci U S A 1996; 93:12496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/28\">",
"      Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/29\">",
"      Heathcote J, McHutchison J, Lee S, et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999; 30:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/30\">",
"      Lau GK, Lok AS, Liang RH, et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997; 25:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/31\">",
"      Lau GK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002; 122:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/32\">",
"      Mehta A, Carrou&eacute;e S, Conyers B, et al. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology 2001; 33:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/33\">",
"      Dh&eacute;din N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998; 66:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23030/abstract/34\">",
"      Weng HL, Wang BE, Jia JD, et al. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 2005; 3:819.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3679 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-714CE7359B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23030=[""].join("\n");
var outline_f22_31_23030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H92258100\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIVIRAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Emtricitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Drugs no longer under development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NOVEL ANTIVIRAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Selective targeting of antiviral agents to the liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antisense approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RNA interference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Non-HBV-specific immunomodulatory therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Thymosin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HBV-specific immunomodulatory therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - S and pre-S antigen vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - DNA vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - T cell vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Adoptive immunity transfer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Alpha-glucosidase inhibitor derivatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      THERAPY AIMED AT IMPROVING FIBROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92258100\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=related_link\">",
"      Characteristics of the hepatitis B virus and pathogenesis of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=related_link\">",
"      Combination therapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=related_link\">",
"      Emerging therapies for hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_31_23031="Colistin: An overview";
var content_f22_31_23031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Colistin: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23031/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23031/contributors\">",
"     Graeme MacLaren, MBBS, FCICM, FRACP, FCCP, FCCM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23031/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23031/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23031/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23031/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23031/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/31/23031/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     Colistin",
"    </a>",
"    (also called polymyxin E) belongs to the polymyxin group of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/1\">",
"     1",
"    </a>",
"    ]. It was first isolated in Japan in 1949 from Bacillus polymyxa var. colistinus and became available for clinical use in 1959 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Colistin was given as an intramuscular injection for the treatment of Gram-negative infections, but fell out of favor after aminoglycosides became available because of its significant side effects. It was later used as topical therapy as part of selective digestive tract decontamination and is still used in aerosolized form for patients with cystic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More recently, a number of centers around the world have used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    intravenously for otherwise panresistant nosocomial infections, especially those due to Pseudomonas and Acinetobacter spp [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/4-8\">",
"     4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The spectrum of activity, mechanisms of action and resistance, pharmacokinetics, interactions with other drugs, and adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    will be reviewed here. The clinical settings in which colistin may be used are discussed separately in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     Colistin",
"    </a>",
"    is a bactericidal drug that binds to lipopolysaccharides and phospholipids in the outer cell membrane of Gram-negative bacteria. It competitively displaces divalent cations from the phosphate groups of membrane lipids, which leads to disruption of the outer cell membrane, leakage of intracellular contents, and bacterial death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its bactericidal effect,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    can bind and neutralize lipopolysaccharide (LPS) and prevent the pathophysiologic effects of endotoxin in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    resistance is poorly defined. Overexpression of outer membrane proteins such as OprH, induced by acidic, low-magnesium environments, appears to play a significant role [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In addition, resistance has been associated with a reduction in the net negative charge of the lipid A component of LPS that reduces binding of positively charged colistin; these changes have in some cases been mediated by mutations in the PmrAB two-component regulatory system, which affects cellular metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/15\">",
"     15",
"    </a>",
"    ]. Heteroresistance to colistin has been demonstrated in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=see_link\">",
"     \"Treatment and prevention of Acinetobacter infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=see_link&amp;anchor=H10046302#H10046302\">",
"     \"Overview of antibacterial susceptibility testing\", section on 'Heteroresistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no standardized methods for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    susceptibility testing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/18\">",
"     18",
"    </a>",
"    ]. The broth microdilution method is preferred for susceptibility testing. E-testing correlates well with broth microdilution at low minimum inhibitory concentrations (MIC between 0.25 and 1",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    but less reliably at more extreme dilutions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/19\">",
"     19",
"    </a>",
"    ]. The disk diffusion method cannot be used to test for resistance since polymyxins diffuse poorly in agar [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/20\">",
"     20",
"    </a>",
"    ]. Agar dilution and Vitek2 have also been used, but their reliability is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    is uncommon. The relative lack of resistance may be at least partially explained by the detergent properties of colistin, which function independently of bacterial metabolic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/24\">",
"     24",
"    </a>",
"    ]. In a surveillance survey of 417 P. aeruginosa strains isolated from cystic fibrosis patients in the United Kingdom, only 13 isolates were resistant to colistin (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/25\">",
"     25",
"    </a>",
"    ]. A second survey of P. aeruginosa isolates from cystic fibrosis patients in Germany found colistin resistance in 5 of 156 mucoid isolates (3.2 percent) and 35 of 229 non-mucoid isolates (15.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     Colistin",
"    </a>",
"    has a narrow antibacterial spectrum and is primarily used for infections with P. aeruginosa and A. baumannii. Other susceptible organisms include Escherichia coli, some Enterobacter spp, Haemophilus influenzae, Bordetella pertussis, Legionella pneumophila, Klebsiella spp, Salmonella spp, Shigella spp, and the majority of Stenotrophomonas maltophilia strains (74 percent of 23 tested isolates in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, Burkholderia cepacia, Serratia marcescens, Moraxella catarrhalis, Proteus spp, Providencia spp, and Morganella morganii are all resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    . Other inherently resistant organisms include all Gram-positive bacteria and Gram-negative cocci. Organisms with variable resistance include Aeromonas, Vibrio, Prevotella, and Fusobacterium spp [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/3,24,27\">",
"     3,24,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     Colistin",
"    </a>",
"    is available as both colistin sulfate and colistimethate sodium (CMS). Neither form is absorbed from the gastrointestinal tract. Colistin sulfate is formulated only as topical and nonabsorbable oral products. CMS is a prodrug that is hydrolyzed after intravenous administration to produce several derivatives, including the active drug colistin. Colistin is tightly bound to membrane lipids of cells of many body tissues, including the liver, lung, kidney, brain, heart, and muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/28\">",
"     28",
"    </a>",
"    ]. Data on the pharmacokinetics of intravenous CMS are sparse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. CMS has a half-life of 124 minutes, whereas colistin (base) has a half-life of 251 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/30\">",
"     30",
"    </a>",
"    ]. Colistin has a calculated volume of distribution of 0.34",
"    <span class=\"nowrap\">",
"     L/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/30\">",
"     30",
"    </a>",
"    ]. CMS is excreted in the urine. No biliary excretion has been reported in humans.",
"   </p>",
"   <p>",
"    The distribution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    to the pleural cavity, lung parenchyma, bones, and cerebrospinal fluid (CSF) is relatively poor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Colistin CSF penetration is low (CSF-to-serum ratio of 5 percent) and bactericidal concentrations are inadequate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/33\">",
"     33",
"    </a>",
"    ]. Failure of intravenous colistin alone in Acinetobacter ventriculitis has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/34\">",
"     34",
"    </a>",
"    ]. However, there are reports of successful treatment with intrathecal colistin for central nervous system infection due to multidrug resistant Gram-negative organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     Colistin",
"    </a>",
"    penetration into other tissues may be adequate for clinical use in some cases. There are reports of successful treatment of deep prosthetic joint and central nervous system infections with intravenous colistin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DOSING AND ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Systemic administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two formulations are commercially available for parenteral use. Both contain colistimethate sodium powder for reconstitution, but they are formulated differently and have distinct dosing recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/37\">",
"     37",
"    </a>",
"    ]. The product available in the United States is supplied in vials containing 150 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    base activity per vial. The product available in many European countries is provided in vials of 1 and 2 million international units of colistimethate sodium; 150 mg colistin base activity is equivalent to approximately 5 million international units of colistimethate sodium. In patients with renal dysfunction, the systemic dose must be modified. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     \"Colistin (colistimethate): Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the United States product, the recommended dose with normal renal function is 2.5 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      base activity divided into two to four equal doses (equivalent to approximately 83,375 to 166,750",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per day of colistimethate sodium) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With the European product, for a person &lt;60 kg, the recommended dosing by the manufacturers is 50,000 to 75,000",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per day, in three divided doses. The maximum daily dose for persons &gt;60 kg is 6 million units.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ideal dose for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    remains uncertain. Results from a small retrospective study of 76 patients with bacteremia due to carbapenem-resistant gram-negative organisms suggest that higher colistin doses within the recommended range are associated with improved microbiological outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/38\">",
"     38",
"    </a>",
"    ]. However, even at high doses, plasma levels of the drug may not initially be high enough to sufficiently exceed the minimum inhibitory concentrations (MIC) for certain gram-negative organisms. As an example, in a study of 18 patients receiving colistin (3 million units colistimethate sodium every eight hours), plasma concentrations of colistin prior to reaching steady state were less than the MICs of the target organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/39\">",
"     39",
"    </a>",
"    ]. Some authors have therefore suggested dose alterations, including delivery of a loading dose, to achieve therapeutic levels more rapidly. In a study of 105 critically ill patients who received colistin at various doses, pharmacokinetic modeling supported the use of a loading dose to achieve desired concentrations of colistin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/40\">",
"     40",
"    </a>",
"    ]. This loading dose concept was tested in 25 critically ill patients with 28 clinical episodes of bacteremia or ventilator associated pneumonia due to Gram-negative bacilli that were sensitive only to colistin and, in some cases, an aminoglycoside [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/41\">",
"     41",
"    </a>",
"    ]. Colistimethate sodium was administered in a loading dose of 9 million units followed by 4.5 million units every 12 hours, with the interval adjusted for renal insufficiency. An aminoglycoside or a carbapenem was co-administered in 14 cases. Clinical cure was obtained in 82 percent. Despite the lack of a control group, this study suggests that such an alternative colistin dosing regimen is efficacious.",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    is nephrotoxic, there is concern about increasing renal adverse effects with the use of higher doses. In the loading dose study described above [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/41\">",
"     41",
"    </a>",
"    ], reversible acute kidney injury occurred in 17 percent of cases, all of whom were able to complete therapy with dose modifications. This incidence of nephrotoxicity is comparable to historical rates when loading doses were not used. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Nephrotoxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Until further clinical data on safety and efficacy are available, we do not recommend the use of a loading dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inhaled administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     Colistin",
"    </a>",
"    can be inhaled via nebulizer and has been used in certain settings, including adjunctive therapy to intravenous antibiotics for nosocomial pneumonia due to multidrug-resistant organisms. It has also been used in management of patients with cystic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link&amp;anchor=H18#H18\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Inhaled colistin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there is minimal evidence of benefit when used in patients with gram-negative pneumonia. In a recent study, aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    resulted in no extra benefit when given as an adjunct to intravenous colistin to patients with multidrug-resistant gram-negative ventilation associated pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/42\">",
"     42",
"    </a>",
"    ].",
"    <em>",
"    </em>",
"    In a separate study, inhaled colistin was compared with inhaled saline in patients with ventilator-associated pneumonia caused by either A. baumannii or P. aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/43\">",
"     43",
"    </a>",
"    ]. Although patients who used inhaled colistin had increased microbial eradication from the respiratory secretions, they had no difference in clinical outcomes and had an increased rate of bronchospasm compared with patients who used inhaled saline.",
"   </p>",
"   <p>",
"    If inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    is used it should be administered with caution. There is the concern that its use may select for resistance to colistin in organisms that are already widely resistant to other agents. In addition, the drug breakdown products can cause direct damage to lung tissue, leading to potentially serious and life-threatening side effects. This is particularly true for the premixed, ready to use liquid forms of the products. If colistin is to be used for nebulized inhalation, it must be mixed IMMEDIATELY prior to administration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    depends on which product is used. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     \"Colistin (colistimethate): Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important side effect of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    is nephrotoxicity; neurotoxicity also occurs, although the frequency and severity are harder to define.",
"   </p>",
"   <p>",
"    The following provides a brief summary of some of the major adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    . These issues are discussed separately. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     \"Colistin (colistimethate): Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     Colistin",
"    </a>",
"    has been associated with hematuria, proteinuria, and oliguria and acute renal failure due to acute tubular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/4,6,8,45,46\">",
"     4,6,8,45,46",
"    </a>",
"    ]. It may be difficult to determine the relative contribution of colistin to development of acute renal failure since patients who receive colistin typically have complex clinical circumstances and many may be receiving other concomitant nephrotoxins. Monitoring of renal function and dose adjustment during colistin administration is critical.",
"   </p>",
"   <p>",
"    The incidence of renal toxicity ranges from 8 to 58 percent, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    -induced renal impairment appears to be reversible [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/1,4,47-50\">",
"     1,4,47-50",
"    </a>",
"    ]. Among 66 patients treated with colistin for multidrug resistant Gram-negative bacterial infections, the incidence of acute renal failure was 45 percent; therapy was stopped because of nephrotoxicity in 21 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/49\">",
"     49",
"    </a>",
"    ]. None of the patients had signs of renal injury at 3 months after treatment. Hypoalbuminemia and concomitant use of non-steroidal anti-inflammatory drugs have been demonstrated to be significant risk factors for colistin induced nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are minimal data on the effects of long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    use. In one study of 17 patients who received intravenous colistin for more than four weeks, no serious toxicity was identified [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/52\">",
"     52",
"    </a>",
"    ]. The median serum creatinine value increased by 0.25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (22",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    during treatment compared with baseline but returned close to the baseline at the end of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neurotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic toxicity is associated with dizziness, weakness, facial and peripheral paresthesia, vertigo, visual disturbances, confusion, ataxia, and neuromuscular blockade, which can lead to respiratory failure or apnea.",
"   </p>",
"   <p>",
"    The incidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    -associated neurotoxicity reported in initial studies was about 7 percent; paresthesias were the main neurotoxic adverse event [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/48\">",
"     48",
"    </a>",
"    ]. Reported toxicity occurred within four days in most patients and was more common in women, but there was no increase in incidence with age.",
"   </p>",
"   <p>",
"    Other neurologic manifestations include psychosis, coma, convulsions, ptosis, diplopia, areflexia, dysphagia and dysphonia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/3,53,54\">",
"     3,53,54",
"    </a>",
"    ]. Neuromuscular blockade is due to non-competitive blockade that, unlike aminoglycoside-induced neuromuscular blockade, is not reversed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In six published series since 1999, only 2 of 230 patients developed suspected",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    neurotoxicity; these manifestations resolved after the drug was discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/4-8,45\">",
"     4-8,45",
"    </a>",
"    ]. However, many of these patients were sedated (and sometimes paralyzed), so subtle neurologic abnormalities may have been difficult to detect.",
"   </p>",
"   <p>",
"    Neurotoxic events related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    therapy appear to occur more frequently in patients with cystic fibrosis. In one series, 21 of 31 patients (68 percent) treated with colistin experienced paresthesias, ataxia, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/29\">",
"     29",
"    </a>",
"    ]. All of these apparent colistin-induced neurologic adverse effects, although bothersome, were benign and reversible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity reactions (including rash, pruritus, urticaria, and fever) have been reported in 2 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/48\">",
"     48",
"    </a>",
"    ]. Aerosolization of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    into the airway can be complicated by bronchospasm; bronchodilation prior to administration may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23031/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     Colistin",
"    </a>",
"    can interact with a variety of other drugs causing increased toxicity. These interactions are discussed separately. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     \"Colistin (colistimethate): Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1082507\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       Colistin",
"      </a>",
"      , or polymyxin E, is a bactericidal drug that disrupts the outer cell membrane of gram-negative rods and is primarily used for infections with Pseudomonas aeruginosa and Acinetobacter baumannii. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acquired resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      is uncommon. However, certain gram-negative rods are intrinsically resistant. These include Burkholderia cepacia, Serratia marcescens, Moraxella catarrhalis, Proteus spp, Providencia spp, and Morganella morganii. Penetration of colistin into the cerebrospinal fluid is low when administered intravenously. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       Colistin",
"      </a>",
"      is formulated as colistimethate sodium for reconstitution for parenteral use. It is measured as grams of colistin base activity in the United States and as international units of colistimethate sodium in Europe. The recommended dosage varies by formulation and manufacturer. Dose adjustments should be made in the setting of renal dysfunction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Systemic administration'",
"      </a>",
"      above and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       \"Colistin (colistimethate): Drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      should be used with caution and must be mixed IMMEDIATELY PRIOR to administration. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Inhaled administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of renal toxicity ranges from 8 to 58 percent, and renal impairment appears to be reversible. Neurologic toxicity, mainly paresthesias, is also associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Adverse reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/1\">",
"      Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/2\">",
"      Kumazawa J, Yagisawa M. The history of antibiotics: the Japanese story. J Infect Chemother 2002; 8:125.",
"     </a>",
"    </li>",
"    <li>",
"     Kucers A, Crowe S, Grayson ML, Hoy JF. The use of antibiotics, 5th, Heinemann, London 1997. p.899.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/4\">",
"      Levin AS, Barone AA, Pen&ccedil;o J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/5\">",
"      Garnacho-Montero J, Ortiz-Leyba C, Jim&eacute;nez-Jim&eacute;nez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/6\">",
"      Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7:R78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/7\">",
"      Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37:e154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/8\">",
"      Michalopoulos AS, Tsiodras S, Rellos K, et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/9\">",
"      Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/10\">",
"      Li J, Turnidge J, Milne R, et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/11\">",
"      Giacometti A, Cirioni O, Ghiselli R, et al. Antiendotoxin activity of antimicrobial peptides and glycopeptides. J Chemother 2003; 15:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/12\">",
"      Warren HS, Kania SA, Siber GR. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob Agents Chemother 1985; 28:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/13\">",
"      Groisman EA, Kayser J, Soncini FC. Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J Bacteriol 1997; 179:7040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/14\">",
"      Young ML, Bains M, Bell A, Hancock RE. Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques. Antimicrob Agents Chemother 1992; 36:2566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/15\">",
"      Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009; 53:3628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/16\">",
"      Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50:2946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/17\">",
"      Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 59:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/18\">",
"      Levin AS. Treatment of Acinetobacter spp infections. Expert Opin Pharmacother 2003; 4:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/19\">",
"      Arroyo LA, Garc&iacute;a-Curiel A, Pach&oacute;n-Iba&ntilde;ez ME, et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol 2005; 43:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/20\">",
"      Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/21\">",
"      Lo-Ten-Foe JR, de Smet AM, Diederen BM, et al. Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob Agents Chemother 2007; 51:3726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/22\">",
"      Tan TY, Ng LS, Poh K. Susceptibility testing of unconventional antibiotics against multiresistant Acinetobacter spp. by agar dilution and Vitek 2. Diagn Microbiol Infect Dis 2007; 58:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/23\">",
"      Tan TY, Ng SY. Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin. Clin Microbiol Infect 2007; 13:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/24\">",
"      Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/25\">",
"      Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003; 58:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/26\">",
"      Sch&uuml;lin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 2002; 49:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/27\">",
"      Karabinis A, Paramythiotou E, Mylona-Petropoulou D, et al. Colistin for Klebsiella pneumoniae-associated sepsis. Clin Infect Dis 2004; 38:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/28\">",
"      Kunin CM, Bugg A. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis 1971; 124:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/29\">",
"      Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001; 41:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/30\">",
"      Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/31\">",
"      Stein A, Raoult D. Colistin: an antimicrobial for the 21st century? Clin Infect Dis 2002; 35:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/32\">",
"      Jim&eacute;nez-Mej&iacute;as ME, Pichardo-Guerrero C, M&aacute;rquez-Rivas FJ, et al. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/33\">",
"      Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009; 53:4907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/34\">",
"      Fernandez-Viladrich P, Corbella X, Corral L, et al. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 1999; 28:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/35\">",
"      Vasen W, Desmery P, Ilutovich S, Di Martino A. Intrathecal use of colistin. J Clin Microbiol 2000; 38:3523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/36\">",
"      Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005; 62:39.",
"     </a>",
"    </li>",
"    <li>",
"     Nation RL, Li J. Polymyxins. In: The Use  of Antibiotics, 6th Ed, Kucers A.  (Ed), Heinemann, London 2010. p.955.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/38\">",
"      Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013; 56:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/39\">",
"      Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/40\">",
"      Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/41\">",
"      Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012; 54:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/42\">",
"      Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010; 51:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/43\">",
"      Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010; 65:2645.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Podcasts &mdash; Colistimethate (marketed as Coly-Mycin M and generic products) file://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm077907.htm (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/45\">",
"      Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/46\">",
"      Goverman J, Weber JM, Keaney TJ, Sheridan RL. Intravenous colistin for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population. J Burn Care Res 2007; 28:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/47\">",
"      Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006; 43 Suppl 2:S89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/48\">",
"      Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/49\">",
"      Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/50\">",
"      Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/51\">",
"      Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009; 34:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/52\">",
"      Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/53\">",
"      WOLINSKY E, HINES JD. Neurotoxic and nephrotoxic effects of colistin patients with renal disease. N Engl J Med 1962; 266:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/54\">",
"      Lindesmith LA, Baines RD Jr, Bigelow DB, Petty TL. Reversible respiratory paralysis associated with polymyxin therapy. Ann Intern Med 1968; 68:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23031/abstract/55\">",
"      Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001; 7:434.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 486 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23031=[""].join("\n");
var outline_f22_31_23031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1082507\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DOSING AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Systemic administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inhaled administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1082507\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=related_link\">",
"      Colistin (colistimethate): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=related_link\">",
"      Overview of antibacterial susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=related_link\">",
"      Treatment and prevention of Acinetobacter infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_31_23032="Natalizumab for relapsing-remitting multiple sclerosis in adults";
var content_f22_31_23032=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natalizumab for relapsing-remitting multiple sclerosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23032/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23032/contributors\">",
"     Michael J Olek, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23032/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23032/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23032/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23032/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/31/23032/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    is an effective drug for the treatment of relapsing-remitting multiple sclerosis (RRMS). However, its use is rarely associated with the development of progressive multifocal leukoencephalopathy (PML), a potentially fatal complication.",
"   </p>",
"   <p>",
"    This topic will review the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    for the treatment of refractory or aggressive RRMS in adults. For initial disease modifying therapy of relapsing-remitting multiple sclerosis (RRMS), it is reasonable to begin treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    . These agents are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    is a recombinant monoclonal antibody directed against alpha-4 integrins. The formation of inflammatory lesions in patients with MS may involve lymphocytes and monocytes that gain access to the brain parenchyma from the circulation by first adhering to vascular endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Alpha-4 integrin is expressed on the surface of inflammatory lymphocytes and monocytes and may play a critical role in their adhesion to the vascular endothelium.",
"   </p>",
"   <p>",
"    Treatment with alpha-4 integrin antagonists in rodent models of MS led to reduced signs of disease activity and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In a preliminary six month clinical trial of 213 patients with MS,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    treatment was associated with significantly fewer new enhancing brain lesions on MRI and significantly fewer relapses compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/6\">",
"     6",
"    </a>",
"    ]. In patients with MS, natalizumab treatment is associated with a diminished migratory capacity of immune cells and a prolonged decrease in lymphocyte counts in the cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a 2011 systematic review of trials evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    for relapsing forms of MS, pooled efficacy data from two randomized controlled trials &ndash; AFFIRM and SENTINEL &ndash; showed that natalizumab significantly reduced the risk for having a relapse during two years of treatment (relative risk [RR] 0.57, 95% CI 0.47 to 0.69) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, natalizumab significantly reduced the risk for experiencing progression at two years (RR 0.74, 95% CI 0.62-0.89). The number needed to treat (NNT) to prevent one new exacerbation at two years was 4 (95% CI 3-5) and the NNT to prevent progression at two years was 10 (95% CI 7-23).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the AFFIRM trial, 942 patients with relapsing MS were randomly assigned to receive either monotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      300 mg (n = 627), or placebo (n = 315) by intravenous infusion every four weeks for two years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/10\">",
"       10",
"      </a>",
"      ]. Natalizumab treatment was associated with a statistically significant 68 percent reduction in annualized relapse rate compared with placebo treatment at one year (0.26 versus 0.81), a reduction that was maintained at two years, and with a significant reduction in the cumulative probability of sustained disability progression at two years (17 versus 29 percent).",
"     </li>",
"     <li>",
"      In the SENTINEL trial, 1171 patients with relapsing MS who continued to experience disease activity despite",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      treatment were randomly assigned to also receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      300 mg (n = 589) or placebo (n = 582) by intravenous infusion every four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/11\">",
"       11",
"      </a>",
"      ]. All patients continued to receive interferon beta-1a throughout the trial. The study was stopped about one month early because two patients developed progressive multifocal leukoencephalopathy (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk of progressive multifocal leukoencephalopathy'",
"      </a>",
"      below). Combination therapy (natalizumab plus interferon beta-1a) was associated with a statistically significant 54 percent reduction in annualized relapse rate compared with placebo at one year (0.38 versus 0.82), a difference that was maintained at two years, and with a significant reduction in the risk of sustained disability progression at two years (23 versus 29 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    was beneficial in all analyses of primary and secondary endpoints in both the AFFIRM and SENTINEL trials, indicating the robust nature of the results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As an example, natalizumab treatment as monotherapy (in AFFIRM) or combination therapy (in SENTINEL) was associated with an 83 percent reduction in the number of new or enlarging hyperintense lesions on T2-weighted MRI. Finally, natalizumab treatment was associated with improved health-related quality of life compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reduction in the annualized relapse rate seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    in these trials (54 to 68 percent) compares favorably to the reduction seen with interferon beta or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    treatment in clinical trials (about 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/13\">",
"     13",
"    </a>",
"    ]. However, indirect comparisons of effectiveness across trials do not provide compelling evidence of an advantage for natalizumab, and there are no randomized trials comparing natalizumab directly with other disease modifying agents. In the absence of such trials, the 2008 AAN guidelines concluded that the relative effectiveness of natalizumab compared with current disease modifying agents cannot be defined accurately [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    treatment is associated with a risk of developing progressive multifocal leukoencephalopathy (PML), a rare potentially fatal neurologic disease caused by reactivation of JC virus infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link&amp;anchor=H2#H2\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    was withdrawn from the market in early 2005 after two patients receiving the drug to treat MS developed confirmed PML, which was the cause of death in one [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. PML was also reported in a patient treated with natalizumab for Crohn's disease. A relationship between natalizumab therapy and the onset of PML was supported by the detection &mdash; after initiation of natalizumab therapy &mdash; of a new and rising JC viral load in serum that preceded the onset of neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. Natalizumab was reintroduced to the US and European markets in mid 2006 for use only as monotherapy to treat relapsing forms of MS. Thereafter additional cases of PML associated with natalizumab therapy began to emerge. By February 2012, 212 cases of PML associated with natalizumab therapy had been reported worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric treatment of PML associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17336?source=see_link&amp;anchor=H12#H12\">",
"     \"Progressive multifocal leukoencephalopathy: Prognosis and treatment\", section on 'Natalizumab-associated PML'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7950870\">",
"    <span class=\"h2\">",
"     PML risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    -associated PML include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous infection with JC virus as suggested by baseline seropositivity for anti-JC virus antibodies",
"     </li>",
"     <li>",
"      Prior immunosuppressant treatment",
"     </li>",
"     <li>",
"      Duration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2012 review of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    -associated PML in patients with MS evaluated data from three clinical trials and a registry of patients with MS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/19\">",
"     19",
"    </a>",
"    ]. For patients treated with natalizumab for MS, the overall estimated incidence of PML was 2.1 per 1000 patients (95% CI 1.9-2.4). However, among 54 patients with available serum samples who developed natalizumab-related PML, the seropositive rate for anti-JC virus antibodies prior to the diagnosis of PML was 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/19\">",
"     19",
"    </a>",
"    ]. In contrast, among all 5896 patients with MS who were enrolled in the controlled trials and registries, the seropositive rate for anti-JC virus antibodies was approximately 55 percent. These data and information about prior immunosuppressant treatment were used to refine the estimates for the risk of natalizumab-associated PML as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who were seronegative at baseline for anti-JC virus antibodies, the estimated risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      -associated PML was &le;0.09 per 1000 (95% CI 0.0-0.48) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/19\">",
"       19",
"      </a>",
"      ]. This analysis assumed that PML developed in one hypothetical patient negative for anti-JC virus antibodies at baseline, a reasonable assumption since the false negative rate of the anti-JC virus antibody assay is approximately 3 percent.",
"     </li>",
"     <li>",
"      For patients who were seropositive for anti-JC virus antibodies but had no prior exposure to immunosuppressant treatment, the estimated risk of PML with 1 to 24 months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      treatment was 0.56 per 1000 patients (95% CI 0.36&ndash;0.83) and for 25 to 48 months of treatment was 4.6 per 1000 (95% CI 3.7&ndash;5.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients who were both seropositive for anti-JC virus antibodies and had previous immunosuppressant treatment (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , or a combination), the estimated PML risk with 1 to 24 months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      treatment was 1.6 per 1000 patients (95% CI 0.9-2.6) and the estimated risk for 25 to 48 months of treatment was 11.1 per 1000 (95% CI 8.3-14.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another study derived similar estimates for the risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    -associated PML (",
"    <a class=\"graphic graphic_table graphicRef55637 \" href=\"UTD.htm?30/0/30731\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data confirm that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    , even as monotherapy, is a risk factor for PML [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. In addition, they suggest that previous immunosuppressant treatment increases the risk of natalizumab-associated PML by three- to four-fold, and that the highest risk is seen in patients who are seropositive for anti-JC virus antibodies at baseline, have prior immunosuppressant treatment, and received natalizumab for more than 24 months.",
"   </p>",
"   <p>",
"    In contrast to JC virus antibodies, testing for JC virus DNA in blood or urine appears to have no utility for determining the risk of PML. Although a small early study suggested that subclinical reactivation of JC virus was frequent in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    for MS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/22\">",
"     22",
"    </a>",
"    ], this was not confirmed in larger investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OTHER SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two large, randomized, controlled trials, adverse events associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    treatment (other than progressive multifocal leukoencephalopathy) included fatigue, allergic reactions, anxiety, pharyngitis, sinus congestion, and peripheral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Natalizumab should be discontinued in patients who develop hypersensitivity reactions.",
"   </p>",
"   <p>",
"    Other potential side effects have been reported in small numbers of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       Natalizumab",
"      </a>",
"      treatment may increase the risk of melanoma in patients with atypical moles, ocular nevi, or a family history of melanoma. This hypothesis is based upon a report of two women with MS who had long-standing nevi and subsequently developed melanoma in close temporal relationship with the start of natalizumab therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinically significant liver injury has been observed in a few patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. Signs of hepatic injury, including markedly elevated serum hepatic enzymes and elevated total bilirubin, occurred as early as six days after the first dose of natalizumab. Therefore, natalizumab should be discontinued in patients with jaundice or other evidence of significant liver injury.",
"     </li>",
"     <li>",
"      There are case reports of unusual infections that developed after months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      therapy, including nonfatal herpes simplex virus encephalitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/28\">",
"       28",
"      </a>",
"      ] and tuberculosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Asymptomatic hypereosinophilia has occurred in several patients during treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H726232333\">",
"    <span class=\"h2\">",
"     Antibodies to natalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    developed in approximately 9 percent of patients in the AFFIRM and SENTINEL trials, and these antibodies were persistently positive in about 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/31\">",
"     31",
"    </a>",
"    ]. When compared with antibody negativity, persistent anti-natalizumab antibody positivity was associated with reduced clinical effectiveness of natalizumab treatment (as measured by disability progression, relapse rate, and MRI lesion formation) and with an increased incidence of infusion reactions.",
"   </p>",
"   <p>",
"    The authors of the study suggest testing for antibodies after six months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    therapy in patients who have continued clinical MS activity or persistent infusion reactions, and stopping natalizumab if antibody positivity is confirmed by retesting after three more months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines published in 2008 by the American Academy of Neurology (AAN) recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    be reserved for the treatment of selected patients with RRMS who have failed other therapies because of continued disease activity or medication intolerance, or who have a very aggressive initial disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/14\">",
"     14",
"    </a>",
"    ]. The guidelines also recommend that natalizumab",
"    <strong>",
"     not",
"    </strong>",
"    be used in combination with beta interferons because the combination may increase the risk of progressive multifocal leukoencephalopathy. Furthermore, the AAN recommends that the combination of natalizumab with agents that do not induce immune suppression should be reserved for clinical trials.",
"   </p>",
"   <p>",
"    Given the data regarding its effectiveness and side effects, particularly the risk of progressive multifocal leukoencephalopathy, we are in general agreement with the AAN guidelines and recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    should be reserved for patients with active RRMS that is refractory or resistant to beta interferons and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    , and for patients who are intolerant of these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H34#H34\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Refractory disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some experts believe that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    is more effective than any other available MS disease modifying treatment and therefore routinely use it early in the course of RRMS, rather than reserving only it for patients who have a high level of early disease activity or for those who are refractory to other agents.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    treatment should not be used in patients who may have impaired immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. We suggest stopping glucocorticoids and other immunomodulators for at least one month prior to starting natalizumab. A longer wash-out period (up to three months or more) is suggested for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/32\">",
"     32",
"    </a>",
"    ]. Leukocyte and neutrophil counts should be within or close to the normal range. Natalizumab is contraindicated in patients who have hematologic or rheumatologic conditions associated with compromised cell-mediated immunity.",
"   </p>",
"   <p>",
"    A brain MRI scan should be obtained prior to initiating therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk management program",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reintroduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    is accompanied by a risk management program (the",
"    <a class=\"external\" href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM107197.pdf\">",
"     TOUCH",
"    </a>",
"    program) that requires enrollment by prescribers as well as 12 specialty pharmacies and approximately 4500 infusion centers that dispense the drug in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/34\">",
"     34",
"    </a>",
"    ]. Clinicians must evaluate patients at three and six months after natalizumab treatment is started, and every six months thereafter. Patients receiving natalizumab will enroll in a mandatory registry and complete a checklist that inquires about medications and new symptoms suggestive of progressive multifocal leukoencephalopathy (PML) prior to monthly infusions.",
"   </p>",
"   <p>",
"    Rigorous follow-up is essential in order to detect the onset of symptoms and signs related to PML as opposed to those related to MS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/20\">",
"     20",
"    </a>",
"    ]. In general, MS relapses are characterized by acute onset, typically occurring over hours to days, with eventual stabilization and resolution, and typical presentations that include diplopia, optic neuritis, and myelopathy. In contrast, PML is characterized by subacute onset over several weeks, progressive disease, and presentations that include aphasia, behavioral and neuropsychiatric abnormalities, cortical visual deficits, hemiparesis, and seizures.",
"   </p>",
"   <p>",
"    When there is suspicion for PML,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    should be discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/20\">",
"     20",
"    </a>",
"    ]. The management of natalizumab-related PML is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17336?source=see_link&amp;anchor=H12#H12\">",
"     \"Progressive multifocal leukoencephalopathy: Prognosis and treatment\", section on 'Natalizumab-associated PML'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10136878\">",
"    <span class=\"h2\">",
"     Drug holiday",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some MS centers employ a three or four month suspension of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    after one year of treatment in order to restore immune surveillance. The rational for doing so is that the risk of progressive multifocal encephalopathy (PML) is believed to be dependent on both the cumulative dose and duration of natalizumab therapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk of progressive multifocal leukoencephalopathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    One concern with this strategy is the possibility that stopping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    may lead to a sudden worsening or rebound of MS disease activity, with rebound defined by an increase in the either the rate or severity of relapses compared with pretreatment disease activity. However, the bulk of the available evidence, though uncontrolled, suggests that disease activity returns to levels similar to pretreatment levels and tends to peak about four months after natalizumab is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/35\">",
"     35",
"    </a>",
"    ]. Additionally, the increase in disease activity is greater for patients with higher pretreatment disease activity, and does not appear to exceed the levels seen in patients randomly assigned to placebo.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest study followed over 1800 patients with MS who were enrolled in the controlled trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      when the trials were suspended and the drug was temporarily withdrawn from the market due to the detection of initial cases of PML [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/36\">",
"       36",
"      </a>",
"      ]. Disease activity began to increase soon after cessation of natalizumab and reached pre-natalizumab levels by four to seven months. In patients with highly active MS, the ARR increased from 0.27 on-treatment to 1.56 at four months after natalizumab discontinuation. Of importance, the level of MS disease activity during the eight month period of natalizumab treatment interruption never exceeds the levels observed in patients who were assigned to placebo in the clinical trials.",
"     </li>",
"     <li>",
"      In a prospective study of 23 patients with MS, there was no significant difference in neurologic disability for the patient cohort before, during, and 14 months after discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/37\">",
"       37",
"      </a>",
"      ]. Most patients were treated with another disease-modifying drug after stopping natalizumab.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies, though limited by small patient numbers, have nevertheless raised concern that a rebound effect or a more severe reaction similar to the immune reconstitution inflammatory syndrome may follow discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. The following reports illustrate this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest published report, which evaluated patients with MS who were treated with 12 or more",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      infusions, clinical relapse within six months of natalizumab suspension occurred in 19 of 68 patients (28 percent) at a median of three months from treatment suspension, compared with none of 16 patients during months 12 to 18 of ongoing natalizumab treatment; the difference was statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/38\">",
"       38",
"      </a>",
"      ]. Among the 19 patients with clinical relapse, seven had a severe flare, with an increase on the Expanded Disability Status Scale from a median of 3.0 to 6.0 and the development of multiple new enhancing lesions on brain MRI (mean 16, range 6 to 40). Only four patients in the study were treated with another disease-modifying agent after discontinuing natalizumab, and none had a relapse.",
"     </li>",
"     <li>",
"      In another study of patients who had received 12 or more consecutive months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      therapy, relapses occurred after mean natalizumab interruption of approximately four months in nine of 24 patients (38 percent) with relapsing-remitting MS and in two of eight patients with secondary progressive MS (SPMS) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/39\">",
"       39",
"      </a>",
"      ]. A third patient with SPMS experienced two severe relapses shortly after restarting natalizumab. In several patients, particularly those with SPMS, the relapses were considered unusually severe with widespread gadolinium lesion enhancement on MRI involving areas of previous demyelination. The mean number of gadolinium-enhancing MRI lesions that occurred after natalizumab discontinuation was significantly greater than the mean number of such lesions observed during attacks prior to starting natalizumab (9.5 versus 2.6). During the period of natalizumab interruption, none of the patients were treated with another disease-modifying therapy.",
"     </li>",
"     <li>",
"      In a series of 10 clinically stable patients with MS who discontinued",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      after 12 to 40 months of therapy, clinical relapse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      new lesions on MRI within six months of treatment interruption on MRI occurred in seven patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23032/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although definitive evidence is lacking, we conclude that a drug holiday of three to four months is unlikely to cause MS rebound but may lead to a return of MS disease activity to the level that was present before",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    treatment. Therefore, we suggest it should not be done routinely, particularly for patients with highly active MS prior to starting natalizumab. However, patient preferences must be considered, and a drug holiday of three to four months after one year of natalizumab treatment is a reasonable option for patients who are more concerned about the risk of developing PML than the risk of increased MS disease activity. For such patients, we suggest treatment with another disease-modifying agent or monthly glucocorticoids for the duration of the natalizumab drug holiday. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with MS who have antibodies to the JC virus are at increased risk of developing PML compared with those who do not have such antibodies. Thus, the results of JV virus antibody testing could influence the decision for individual patients regarding the need for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    drug holidays. (See",
"    <a class=\"local\" href=\"#H7950870\">",
"     'PML risk stratification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=see_link\">",
"       \"Patient information: Multiple sclerosis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       Natalizumab",
"      </a>",
"      is an effective drug for the treatment of relapsing-remitting multiple sclerosis (RRMS). However, its use is rarely associated with the development of progressive multifocal leukoencephalopathy (PML), a potentially fatal complication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The reduction in the annualized relapse rate for RRMS seen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      therapy in randomized trials (54 to 68 percent) compares favorably to the reduction seen with interferon beta drugs or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      treatment in other randomized trials (about 33 percent). However, there are no randomized trials comparing natalizumab directly with other disease modifying agents. Thus, the relative effectiveness of natalizumab for RRMS compared with current disease modifying agents cannot be defined accurately. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall risk of PML with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      therapy is estimated to be approximately 2.1 in 1000. The risk of PML is increased with the duration of natalizumab therapy, prior immunosuppressant treatment, and seropositivity for anti-JC virus antibodies prior to natalizumab treatment (",
"      <a class=\"graphic graphic_table graphicRef55637 \" href=\"UTD.htm?30/0/30731\">",
"       table 1",
"      </a>",
"      ). For patients who are seronegative for JC virus and have no prior history of immunosuppression, the risk of PML in the first 24 months of natalizumab therapy is very low. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk of progressive multifocal leukoencephalopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7950870\">",
"       'PML risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with highly active RRMS who have a poor response to both beta interferons and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      , or intolerance of these immunomodulators, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, some experts routinely use natalizumab early in the course of RRMS. Natalizumab is approved for use as monotherapy only. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      must be followed in a risk management program to monitor for symptoms or signs suggestive of progressive multifocal leukoencephalopathy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk management program'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the risk of PML, some MS centers employ a three or four month suspension (ie, a drug holiday) of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      after one year of treatment in order to restore immune surveillance. Although definitive evidence is lacking, we conclude that a drug holiday of three to four months is unlikely to cause MS rebound but may lead to a return of MS disease activity to the level that was present before natalizumab treatment. For patients with MS who are being treated with natalizumab because of a high pretreatment MS disease activity level, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      employing a drug holiday (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, a natalizumab drug holiday is a reasonable option for patients who are more concerned about the risk of developing PML than the risk of increased MS disease activity. (See",
"      <a class=\"local\" href=\"#H10136878\">",
"       'Drug holiday'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/1\">",
"      Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/2\">",
"      Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/3\">",
"      Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/4\">",
"      Kent SJ, Karlik SJ, Cannon C, et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/5\">",
"      Kent SJ, Karlik SJ, Rice GP, Horner HC. A monoclonal antibody to alpha 4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig. J Magn Reson Imaging 1995; 5:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/6\">",
"      Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/7\">",
"      Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/8\">",
"      St&uuml;ve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/9\">",
"      Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2011; :CD007621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/10\">",
"      Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/11\">",
"      Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/12\">",
"      Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/13\">",
"      Ropper AH. Selective treatment of multiple sclerosis. N Engl J Med 2006; 354:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/14\">",
"      Goodin DS, Cohen BA, O'Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 71:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/15\">",
"      Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/16\">",
"      Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/17\">",
"      Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. N Engl J Med 2005; 353:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/18\">",
"      Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/19\">",
"      Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/20\">",
"      Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/21\">",
"      Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012; 78:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/22\">",
"      Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/23\">",
"      Rudick RA, O'Connor PW, Polman CH, et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010; 68:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/24\">",
"      Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/25\">",
"      Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 2008; 358:647.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Tysabri (natalizumab) Feb 2008. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110608.htm (Accessed on October 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/27\">",
"      Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther 2010; 31:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/28\">",
"      Kwiatkowski A, Gallois J, Bilbault N, et al. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler 2012; 18:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/29\">",
"      Dahdaleh D, Altmann DM, Malik O, Nicholas RS. Breathlessness, night sweats, and weight loss on natalizumab. Lancet 2012; 380:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/30\">",
"      Abbas M, Lalive PH, Chofflon M, et al. Hypereosinophilia in patients with multiple sclerosis treated with natalizumab. Neurology 2011; 77:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/31\">",
"      Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/32\">",
"      Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/33\">",
"      Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007; 356:2622.",
"     </a>",
"    </li>",
"    <li>",
"     U. S. Food and Drug Administration. Tysabri risk minimization action plan: summary of TOUCH. www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM107197.pdf (Accessed on October 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/35\">",
"      Berger JR, Centonze D, Comi G, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010; 68:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/36\">",
"      O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/37\">",
"      St&uuml;ve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009; 72:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/38\">",
"      West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/39\">",
"      Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/40\">",
"      Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010; 68:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23032/abstract/41\">",
"      Rigau V, Mania A, B&eacute;fort P, et al. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 2012; 79:2214.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1700 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23032=[""].join("\n");
var outline_f22_31_23032=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7950870\">",
"      PML risk stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OTHER SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H726232333\">",
"      Antibodies to natalizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk management program",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10136878\">",
"      Drug holiday",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1700\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1700|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/0/30731\" title=\"table 1\">",
"      Calculated risk of natalizumab-related PML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=related_link\">",
"      Patient information: Multiple sclerosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17336?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_31_23033="Nelfinavir: Pediatric drug information";
var content_f22_31_23033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nelfinavir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"    see \"Nelfinavir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/32/43524?source=see_link\">",
"    see \"Nelfinavir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viracept&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Viracept&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Protease Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Use in combination with other antiretroviral agents: HIV infection, treatment: Not approved for use; a reliable, effective dose has not been established; a high interpatient variability in serum drug concentrations occurs; nelfinavir dosing is problematic in neonates, since the drug is best absorbed when taken with a high-fat meal;  further studies are needed (DHHS [pediatric], 2010; Hirt, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"      see \"Nelfinavir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Use in combination with other antiretroviral agents: HIV infection, treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &lt;2 years: Not approved for use; a reliable, effective dose has not been established; high interpatient variability in serum drug concentrations occurs; nelfinavir dosing is problematic in young infants, since the drug is best absorbed when taken with a high-fat meal; further studies are needed (DHHS [pediatric], 2010; Hirt, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-13 years (oral powder or 250 mg tablets): 45-55 mg/kg/dose (maximum: 1250 mg) twice daily or 25-35 mg/kg/dose (maximum: 750 mg) 3 times/day; doses &gt;2500 mg/day have not been studied in children.",
"     <b>",
"      Note:",
"     </b>",
"     Current guidelines rate nelfinavir as an acceptable protease inhibitor for initial therapy in children &ge;2 years only in special circumstances (ie, when preferred and alternative drugs are not available or are not tolerated); due to the high variability of nelfinavir plasma concentrations in children, dosage adjustment utilizing measurement of plasma concentrations and pharmacokinetics may be beneficial (Crommentuyn, 2006; DHHS [pediatric], 2010; Fletcher, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;14 years and Adults: 1250 mg/dose twice daily or 750 mg 3 times/day.",
"     <b>",
"      Note:",
"     </b>",
"     Some adolescent patients require doses higher than adults to achieve similar nelfinavir AUCs; consider the use of serum drug concentrations to guide optimal dosing (DHHS [pediatric], 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild hepatic impairment (Child-Pugh Class A): Use with caution; no dosage adjustment is necessary. In adults, nelfinavir AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     were not significantly different compared to subjects with normal hepatic function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate hepatic impairment (Child-Pugh Class B): Not recommended for use. In adults, nelfinavir AUC was increased by 62% and C",
"     <sub>",
"      max",
"     </sub>",
"     was increased by 22% compared to subjects with normal hepatic function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh Class C): Has not been studied; not recommended for use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Has not been studied; however, since &lt;2% of the drug is eliminated in the urine, renal impairment should have minimal effect on nelfinavir elimination",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viracept&reg;: 50 mg/g (144 g [DSC]) [contains phenylalanine 11.2 mg/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viracept&reg;: 250 mg, 625 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food to enhance bioavailability and decrease kinetic variability.",
"     <b>",
"      Note:",
"     </b>",
"     Due to problems with administration of the oral powder to infants, use of the tablets may be preferred. Tablets can be readily dissolved in water and consumed or mixed with milk or chocolate milk; consume immediately; rinse glass with water and swallow to make sure total dose is consumed; tablets can also be crushed and administered with pudding. Oral powder can be mixed with a small amount of water, milk, formula, dietary supplements, ice cream, or pudding; mixture must be stored under refrigeration if not used immediately; do not store mixture for more than 6 hours; do not mix oral powder with any acidic food or juice (eg, grapefruit, orange, or apple juice or applesauce) because of resulting bitter taste. If coadministered with didanosine, nelfinavir should be administered 2 hours before or 1 hour after didanosine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Dispense in original container; keep container tightly closed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents. (",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F200432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nelfinavir may be confused with nevirapine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Viracept&reg; may be confused with Viramune&reg;, Viramune&reg; XR&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F200430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, flatulence, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Lymphocytes decreased, neutrophils decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, acute iritis, alkaline phosphatase increased, allergic reaction, amylase increased, anemia, anorexia, anxiety, arthralgia, arthritis, back pain, bilirubinemia, body fat redistribution/accumulation, cramps, creatine phosphokinase increased, dehydration, depression, dermatitis, diaphoresis, dizziness, dyspepsia, dyspnea, emotional lability, epigastric pain, eye disorder, fever, folliculitis, fungal dermatitis, gastrointestinal bleeding, GGTP increased, headache, hepatitis, hyperkinesia, hyper-/hypoglycemia, hyperlipemia; hypersensitivity reaction (bronchospasm, rash, edema); hyperuricemia, immune reconstitution syndrome, insomnia, jaundice, kidney calculus, lactic dehydrogenase increased, leukopenia, lipoatrophy, lipodystrophy, liver function tests abnormal, maculopapular rash, malaise, metabolic acidosis, migraine, mouth ulceration, myalgia, myasthenia, myopathy, pain, pancreatitis, paresthesia, pharyngitis, pruritus, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, rhinitis, seizure, sexual dysfunction, sinusitis, sleep disorder, somnolence, suicidal ideation, thrombocytopenia, torsade de pointes, transaminases increased, urine abnormality, urticaria, vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nelfinavir or any component; concurrent therapy with alfuzosin, amiodarone, dihydroergotamine, ergonovine, ergotamine, methylergonovine, midazolam, pimozide, quinidine, sildenafil (when used for the treatment of pulmonary arterial hypertension), or triazolam",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with mild hepatic impairment; use is",
"     <b>",
"      not",
"     </b>",
"     recommended in patients with moderate or severe hepatic impairment; nelfinavir is metabolized in the liver and may also cause hepatitis and/or exacerbate pre-existing hepatic dysfunction. Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established). Lipodystrophy was observed in 28% of children after a median of 49 months of receiving a nelfinavir-containing antiretroviral regimen (Scherpbier, 2006). Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents, including nelfinavir; this syndrome may require further patient assessment and therapy. Powder formulation contains aspartame which is metabolized to phenylalanine and should be avoided or used with caution in patients with phenylketonuria. May cause diarrhea (adults: 14% to 20%; children: 39% to 47%); a secretory diarrhea mediated via a calcium-dependent process may also occur; calcium carbonate administered at the same time as nelfinavir has been used to treat this adverse effect in adults without affecting plasma concentrations of nelfinavir or its major metabolite.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nelfinavir inhibits cytochrome P450 isoenzyme CYP3A and interacts with numerous drugs. Due to potential serious and/or life-threatening drug interactions, some drugs are contraindicated and the following drugs should",
"     <b>",
"      not",
"     </b>",
"     be coadministered with nelfinavir: Astemizole, cisapride, terfenadine, rifampin, St John's wort, lovastatin, simvastatin, or proton pump inhibitors; concurrent use with some anticonvulsants may significantly limit nelfinavir's effectiveness. Use with caution in patients taking strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers, and major CYP3A4 substrates and if coadministered with QT prolonging drugs that are metabolized by CYP3A. Spontaneous bleeding episodes have been reported in patients with hemophilia type A and B receiving protease inhibitors. New onset diabetes mellitus, exacerbations of diabetes, and hyperglycemia have been reported in HIV-infected patients receiving protease inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F200419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2B6 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azithromycin (Systemic): Nelfinavir may increase the serum concentration of Azithromycin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Nelfinavir. Nelfinavir may increase the serum concentration of Bosentan. Management: Initiate bosentan at, or adjust bosentan dose to, 62.5 mg once daily or every other day (based on tolerability) in patients who receive nelfinavir.  Additionally, monitor for possible reduced clinical response to nelfinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir, saquinavir, and lopinavir (with low-dose ritonavir). Management: Low-dose ritonavir boosting must be used when any protease inhibitor is used with etravirine.  Avoid use of etravirine in combination with atazanavir, fosamprenavir, full-dose ritonavir (600 mg twice daily), or tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase the serum concentration of Nelfinavir. Concentrations of the nelfinavir M8 metabolite may also be increased. Nelfinavir may decrease the serum concentration of Lopinavir. Management: Avoid once daily use of lopinavir/ritonavir with nelfinavir.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for recommended dose increases in other patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Protease Inhibitors may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease serum concentrations of the active metabolite(s) of Nelfinavir. Nevirapine may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Nelfinavir may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Nelfinavir may decrease the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Nelfinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Nelfinavir may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Nelfinavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with nelfinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Nelfinavir may decrease the serum concentration of Warfarin. Nelfinavir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food enhances bioavailability and decreases pharmacokinetic variability. A bitter taste will result if the oral powder formulation is mixed with acidic food or juice",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F200378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Nelfinavir crosses the placenta. A modest increased risk of overall birth defects has been observed following first trimester exposure in humans according to data collected by the antiretroviral pregnancy registry. However, no pattern of defects has been detected. The DHHS Perinatal HIV Guidelines recommend nelfinavir to be used only in special circumstances during pregnancy for the prophylaxis of perinatal transmission in antiretroviral-naive women when alternative agents cannot be tolerated. A dose of 1250 mg twice daily has been shown to provide adequate plasma concentrations although lower and variable levels may occur late in pregnancy. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, blood glucose levels, CBC with differential, CD4 cell count, plasma levels of HIV RNA",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A protease inhibitor which acts on an enzyme (protease) late in the HIV replication process after the virus has entered into the cell's nucleus; nelfinavir binds to the protease activity site and inhibits the activity of the enzyme, thus preventing cleavage of viral polyprotein precursors (gag-pol protein precursors) into individual functional proteins found in infectious HIV; this results in the formation of immature, noninfectious viral particles",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: AUC is two- to threefold higher under fed conditions versus fasting; AUC is highly variable in pediatric patients due to increased clearance, problems with compliance, and inconsistent food intake with dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 2-7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via multiple cytochrome P450 isoforms including CYP3A4 and CYP2C19; one active oxidative metabolite with comparable activity to the parent drug and several minor oxidative metabolites are formed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Adults: 20% to 80%;",
"     <b>",
"      Note:",
"     </b>",
"     The 625 mg and 250 mg tablet formulations were shown to be bioequivalent in HIV-infected patients receiving multiple doses of 1250 mg twice daily (under fed conditions). In healthy volunteers, the 250 mg and 625 mg tablets were",
"     <b>",
"      not",
"     </b>",
"     bioequivalent; the AUC for the 625 mg tablets was 34% higher than the 250 mg tablets in fasted adults and 24% higher than the 250 mg tablets under fed conditions. Nelfinavir concentrations following a single 750 mg dose using the 250 mg tablets were similar to those after administration of the oral powder, under fed conditions in healthy volunteers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 3.5-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 98% to 99% excreted in feces (78% as metabolites and 22% as unchanged nelfinavir); 1% to 2% excreted in urine (primarily as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/32/43524?source=see_link\">",
"      see \"Nelfinavir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nelfinavir is not a cure for HIV. Some medications should not be taken with nelfinavir; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist; avoid the herbal medicine St John's wort. Use an alternative method of contraception to birth control pills during nelfinavir therapy. If a nelfinavir dose is missed, take the dose as soon as possible and then return to the normal schedule. However, if a dose is skipped, do not double the next dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Briars LA, Hilao JJ, and Kraus DM, &ldquo;A Review of Pediatric Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Journal of Pharmacy Practice",
"      </i>",
"      , 2004, 17(6):407-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crommentuyn KM, Scherpbier HJ, Kuijpers TW, et al, \"Population Pharmacokinetics and Pharmacodynamics of Nelfinavir and Its Active Metabolite M8 in HIV-1-Infected Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2006, 25(6):538-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23033/abstract-text/16732153/pubmed\" id=\"16732153\" target=\"_blank\">",
"        16732153",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" October 14, 2011, 1-167. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" August 11, 2011. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fletcher CV, Brundage RC, Fenton T, et al, \"Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in HIV-Infected Children Participating in an Area-Under-the-Curve Controlled Trial,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2008, 83(2):300-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23033/abstract-text/17609682/pubmed\" id=\"17609682\" target=\"_blank\">",
"        17609682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirt D, Urien S, Jullien V, et al, \"Age-Related Effects on Nelfinavir and M8 Pharmacokinetics: A Population Study With 182 Children,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2006, 50(3):910-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23033/abstract-text/16495250/pubmed\" id=\"16495250\" target=\"_blank\">",
"        16495250",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDonald CK and Kuritzkes DR, &ldquo;Human Immunodeficiency Virus Type I Protease Inhibitors,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1997, 157(9):951-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23033/abstract-text/9140265/pubmed\" id=\"9140265\" target=\"_blank\">",
"        9140265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scherpbier HJ, Bekker V, van Leth F, et al, \"Long-Term Experience With Combination Antiretroviral Therapy That Contains Nelfinavir for Up to 7 Years in a Pediatric Cohort,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(3):e528-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/31/23033/abstract-text/16481448/pubmed\" id=\"16481448\" target=\"_blank\">",
"        16481448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12960 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-74FB0B1AEA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23033=[""].join("\n");
var outline_f22_31_23033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200394\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200395\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054317\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443896\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054309\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200369\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200354\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054321\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054312\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054320\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200432\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200430\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054324\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054308\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054307\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200419\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200363\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054326\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200365\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200378\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054316\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054306\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054323\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054314\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12960\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12960|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=related_link\">",
"      Nelfinavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/32/43524?source=related_link\">",
"      Nelfinavir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_31_23034="Clinical manifestations of the antiphospholipid syndrome";
var content_f22_31_23034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of the antiphospholipid syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23034/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23034/contributors\">",
"     Bonnie L Bermas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23034/contributors\">",
"     Doruk Erkan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23034/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23034/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23034/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/31/23034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/31/23034/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/31/23034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiphospholipid syndrome (APS) is defined by two major components (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Classification criteria'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The occurrence of at least one clinical feature: vascular event or pregnancy morbidity",
"     </li>",
"     <li>",
"      The presence of at least one type of autoantibody known as an antiphospholipid antibody (aPL) on two separate occasions at least 12 weeks apart",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there are aPL-related clinical manifestations that are not part of the APS classification criteria, such as livedo reticularis, thrombocytopenia, cardiac valve disease, and aPL-nephropathy.",
"   </p>",
"   <p>",
"    Although the clinical manifestations of APS occur in other disease populations, in the APS, they occur in the context of aPL. aPL are directed against serum proteins bound to anionic phospholipids and may be detected by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lupus anticoagulant tests",
"     </li>",
"     <li>",
"      Anticardiolipin antibody ELISA",
"     </li>",
"     <li>",
"      Anti-&szlig;2 glycoprotein-I ELISA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The full clinical significance of other antiphospholipid antibodies, including those directed against prothrombin, annexin V, phosphatidylserine, and phosphatidylinositol, remains unclear.",
"   </p>",
"   <p>",
"    APS occurs as a primary condition or in the setting of an underlying systemic autoimmune disease, particularly systemic lupus erythematosus (SLE).",
"   </p>",
"   <p>",
"    The clinical manifestations of APS will be reviewed here. The pathogenesis, diagnosis, and treatment of this disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"     \"Pathogenesis of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link\">",
"     \"Diagnosis of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different aPL and their serologic assays are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link\">",
"     \"Diagnosis of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"     \"Pathogenesis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As background to a discussion of the clinical manifestations of the APS, we will summarize briefly the relationships between the three major aPL, one or more of which is present in patients with APS:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anticardiolipin antibodies (aCL)",
"     </li>",
"     <li>",
"      Antibodies to &szlig;2-glycoprotein-I (&szlig;2-GP-I)",
"     </li>",
"     <li>",
"      Lupus anticoagulant (LA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160817402\">",
"    <span class=\"h2\">",
"     aCL and &szlig;2-GP-I assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;aPL binding to phospholipids is mediated through non-immunoglobulin phospholipid-binding plasma proteins. &szlig;2-GP-I is the main antigenic target of aPL. Some experienced clinical laboratories can distinguish between:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies to cardiolipin and other phospholipids",
"     </li>",
"     <li>",
"      Antibodies to cardiolipin that require the presence of &szlig;2-GP-I for binding and those that do not. However, such assays are not generally commercially available.",
"     </li>",
"     <li>",
"      Antibodies binding to &szlig;2-GP-I that are independent of the presence of phospholipids and those for which phospholipids are required",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antibody levels for aCL of IgG and IgM type are reported in units as GPL and MPL, respectively. Recommendations for a standard approach to testing and reporting were published in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'Antiphospholipid antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &szlig;2-GP-I is the most common target of aPL. This protein, also known as apolipoprotein H, becomes antigenic upon binding to a negatively charged surface. The relevance of this feature is that positive aCL ELISAs with clinical features of APS are usually caused by the binding of anti-&szlig;2-GP-I antibodies. Patients who have positive aCL by ELISA but negative assays for anti-&szlig;2-GP-I antibodies may be at a substantially lower or no increased risk for clotting, but additional work in this area is required.",
"   </p>",
"   <p>",
"    Prior to the development of the aCL assay, it was recognized that patients with a history of a false positive test for syphilis might have a positive lupus anticoagulant (LA) test and symptoms of what became known as APS. A false positive test for syphilis used to be part of the criteria for the diagnosis of SLE, but it has now been replaced by the three tests for aPL (ie, aCL, anti-&beta;2-GP-I, and LA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160817409\">",
"    <span class=\"h2\">",
"     Lupus anticoagulant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lupus anticoagulant phenomenon refers to the ability of aPL to cause prolongation of in vitro clotting assays such as the activated partial thromboplastin time (aPTT), the dilute Russell viper venom time (dRVVT), the kaolin clotting time, or, infrequently, the prothrombin time. This prolongation is not reversed when the patient's plasma is diluted 1:1 with normal platelet-free plasma. In contrast, such mixing studies would correct the clotting abnormality associated with factor deficiencies. Thus, the term &ldquo;the lupus anticoagulant&rdquo; is a misnomer; it is generally associated with a clotting tendency rather than an anticoagulant effect.",
"   </p>",
"   <p>",
"    One common effect of aPL detected by routine laboratory testing is the prolongation of the aPTT. However, only about one-half of patients with LAs have prolongations of the aPTT. Thus, if APS is suspected strongly, additional testing, usually with a dRVVT, is essential.",
"   </p>",
"   <p>",
"    Laboratory experience is important in LA assays. In one study, one-quarter of all plasma samples diagnosed as having LA activity were found to be false-positive tests upon measurement in a reference laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/2\">",
"     2",
"    </a>",
"    ]. Guidelines for the detection of LAs are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of the antiphospholipid syndrome\", section on 'Lupus anticoagulant'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of the antiphospholipid syndrome\", section on 'Detection of aPL during anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to prothrombin, annexin V, phosphatidylserine, and other proteins have also been associated with APS. However, understanding of the potential roles played by such antibodies in APS is incomplete, and assays for these antibodies are not part of the standard evaluation when APS is suspected. Antibodies to prothrombin are associated with bleeding as well as thrombosis. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Bleeding episodes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In one study of 101 patients with SLE, the presence of IgG antibodies to prothrombin was associated with thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/3\">",
"     3",
"    </a>",
"    ]. Furthermore, the presence of LA, aCL antibodies, anti-&szlig;2-GP-I antibodies, and anti-prothrombin antibodies conferred a 30-fold increased risk for thrombosis.",
"   </p>",
"   <p>",
"    In summary, the basic science behind APS is an evolving field. Assays for aPL continue to undergo processes of discovery and refinement. For clinical purposes, three types of aPL tests are usually performed when APS is suspected: the LA test, the aCL ELISA, and the anti-&szlig;2-GP-I ELISA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OTHER ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various aPL may be present in some people who are otherwise healthy, who have autoimmune or rheumatic disease, or who have been exposed to certain drugs or infectious agents. These and other associations are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H18#H18\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'Prevalence in different conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLASSIFICATION CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification criteria have been developed for research purposes. They may be helpful to clinicians, but not all the classification criteria need to be met to make a clinical diagnosis of APS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link\">",
"     \"Diagnosis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    International consensus conferences have proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/4\">",
"     4",
"    </a>",
"    ] and revised [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/5\">",
"     5",
"    </a>",
"    ] classification criteria for definite APS. Definite APS is considered present if at least one of the following clinical criteria and at least one of the following laboratory criteria are satisfied.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical &mdash; One or more episodes of venous, arterial, or small vessel thrombosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      morbidity with pregnancy, defined as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thrombosis &mdash; Unequivocal imaging or histologic evidence of thrombosis in any tissue or organ",
"     </li>",
"     <li>",
"      Pregnancy morbidity &mdash; Otherwise unexplained death at &ge;10 weeks gestation of a morphologically normal fetus;",
"      <strong>",
"       or",
"      </strong>",
"      one or more premature births before 34 weeks of gestation because of eclampsia, preeclampsia, or placental insufficiency;",
"      <strong>",
"       or",
"      </strong>",
"      three or more embryonic (&lt;10 week gestation) pregnancy losses unexplained by maternal or paternal chromosomal abnormalities or by maternal anatomic or hormonal causes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory &mdash; The presence of aPL, on two or more occasions at least 12 weeks apart and no more than five years prior to clinical manifestations, as demonstrated by one or more of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      IgG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgM aCL in moderate or high titer (&gt;40 units GPL or MPL or &gt;99th percentile for the testing laboratory)",
"     </li>",
"     <li>",
"      Antibodies to &szlig;2-GP-I of IgG or IgM isotype at a titer &gt;99th percentile for the testing laboratory when tested according to recommended procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      LA activity detected according to published guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic pathologic finding in APS is a bland thrombosis with minimal vascular or perivascular inflammation (",
"    <a class=\"graphic graphic_picture graphicRef52775 \" href=\"UTD.htm?24/63/25590\">",
"     picture 1",
"    </a>",
"    ). This change is not specific for APS, as it also occurs in a variety of other disorders including the hemolytic-uremic",
"    <span class=\"nowrap\">",
"     syndrome/thrombotic",
"    </span>",
"    thrombocytopenic purpura, systemic sclerosis (scleroderma), and malignant hypertension. Larger vessels, both arteries and veins, may develop in situ thrombosis or may be sites from or into which emboli originate or lodge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;APS is characterized by venous or arterial thromboses, morbidity occurring in the setting of pregnancy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aPL-related clinical manifestations that are not part of the APS classification criteria, such as livedo reticularis, thrombocytopenia, cardiac valve disease, or aPL-nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 1000 patients with either primary or secondary APS, the various disease features were [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deep vein thrombosis &mdash; 32 percent",
"     </li>",
"     <li>",
"      Thrombocytopenia &mdash; 22 percent",
"     </li>",
"     <li>",
"      Livedo reticularis &mdash; 20 percent",
"     </li>",
"     <li>",
"      Stroke &mdash; 13 percent",
"     </li>",
"     <li>",
"      Superficial thrombophlebitis &mdash; 9 percent",
"     </li>",
"     <li>",
"      Pulmonary embolism &mdash; 9 percent",
"     </li>",
"     <li>",
"      Fetal loss &mdash; 8 percent",
"     </li>",
"     <li>",
"      Transient ischemic attack &mdash; 7 percent",
"     </li>",
"     <li>",
"      Hemolytic anemia &mdash; 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In rare patients, APS results in multiorgan failure because of multiple blood vessel occlusions, a condition referred to as &ldquo;catastrophic antiphospholipid syndrome&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Catastrophic APS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to those already mentioned above, other possible aPL-related clinical manifestations include migraine headache, Raynaud phenomenon, pulmonary hypertension, avascular necrosis, cutaneous ulcers that resemble pyoderma gangrenosum, adrenal insufficiency due to hemorrhagic infarction, and cognitive deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/9,10,12-23\">",
"     9,10,12-23",
"    </a>",
"    ]. For some of these clinical entities, the true relationship between the occurrence of the condition and the presence of aPL is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of both venous and arterial thrombosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thromboembolism is increased in individuals with positive tests for LA activity (odds ratio [OR] of 11) or with medium or high levels of aCL (OR 1.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/24\">",
"     24",
"    </a>",
"    ]. The risk of recurrent thrombosis or thromboembolism may be further enhanced in those with positivity to three aPL activities (LA, aCL, and &szlig;2-glycoprotein-I) upon repeated testing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Initial site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thromboses are more common than arterial thromboses in APS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/14,26\">",
"     14,26",
"    </a>",
"    ]. The most common site of deep vein thrombosis (DVT) is the veins of the calf, but the renal veins; the hepatic, axillary, subclavian, and retinal veins; the cerebral sinuses; and the vena cavae may also be involved. The most common site of arterial thrombosis is the cerebral vessels, but coronary, renal, and mesenteric arteries and arterial bypass graft occlusions have also been noted.",
"   </p>",
"   <p>",
"    To some degree, the site of thrombosis may be related to the type of aPL present. This was illustrated in a retrospective study of 637 patients with APS in which DVT and pulmonary emboli (PE) were more frequent among patients with LA, while coronary, cerebrovascular, and peripheral arterial events were more likely in those with elevated levels of IgG or IgM aCL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Deep venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;aPL can be detected in approximately 5 to 21 percent of all patients with DVT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The incidence of DVT may correlate with the level of aCL. As an example of the association of titer and clinical events, one study found that DVT occurred in 44 percent of patients with high titers of aCL, in 29 percent of those with low titers, and in only 10 percent of those without these antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk in asymptomatic persons &mdash; There are conflicting data regarding the question of whether the presence of elevated levels of aCL in otherwise healthy individuals is associated with an increased risk of DVT or PE. Two well-designed prospective case-controlled studies of aCL and venous thrombosis came to different conclusions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a study of 22,071 male clinicians, 90 cases of DVT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PE were matched with 90 controls. An aCL level greater than the 95th percentile for the entire group (&ge;33 GPL) was associated with a relative risk for DVT of 5.3 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in a subsequent study of 21,680 initially healthy men and women, 317 cases of DVT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PE were compared with 655 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/30\">",
"       30",
"      </a>",
"      ]. No significant difference in the risk of DVT or PE was noted for subjects with elevated IgG aCL levels (&ge;95th percentile) or elevated IgM aCL (&ge;28.7 MPL).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of six studies that included the first but not the second study found an overall odds ratio for venous thromboembolism of 1.56 for aCL (95% CI 1.1-2.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/31\">",
"     31",
"    </a>",
"    ]. The odds ratio was substantially higher in the presence of LA activity (11.1; 95% CI 3.8-32.3).",
"   </p>",
"   <p>",
"    As noted above, one possible determinant of the pathogenicity of aCL is whether or not antibodies to &szlig;2-GP-I are present simultaneously with aCL. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'The antibodies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;APS is strongly linked to ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/32\">",
"     32",
"    </a>",
"    ]. The occurrence of livedo reticularis in association with a stroke is known as Sneddon&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/33\">",
"     33",
"    </a>",
"    ]. In the great majority of cases, Sneddon's syndrome is associated with detectable aPL.",
"   </p>",
"   <p>",
"    A thrombotic stroke occurring in a young patient with no overt risk factors for cerebrovascular disease is the classic setting in which to suspect APS. In one study, aPL were found in 25 percent of patients younger than 45 years of age who presented with a stroke of unclear etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/34\">",
"     34",
"    </a>",
"    ]. In another report, 20 percent of stroke victims under the age of 50 had aPL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ischemic stroke may be a manifestation in situ thrombosis or due to embolism arising from valvular heart disease. If routine transthoracic echocardiography is normal, transesophageal echocardiography may be indicated to assess for vegetations due to nonbacterial endocarditis. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Valvular disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several studies have evaluated the risk of stroke associated with the presence of aPL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 2000 healthy male subjects, the relative risk of stroke at 15 years of follow-up was 2.2 in subjects with aPL [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/35\">",
"       35",
"      </a>",
"      ]. Events were observed primarily in subjects who had both &szlig;2-GP-I and IgG aCL (ie, &szlig;2-GP-I dependent aCL).",
"     </li>",
"     <li>",
"      In the Stroke Prevention in Young Women study, the presence of LAs and aCL was evaluated in 160 cases and 340 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/36\">",
"       36",
"      </a>",
"      ]. After adjustment for potential confounders, the relative odds of stroke for women with an aCL of any isotype or an LA was 1.87 (95% CI 1.2-2.8). Similar findings of an increased risk of ischemic stroke associated with aCL limited to women were noted in a report from the Framingham Cohort and Offspring Study (hazard ratio for women 2.6; 95% CI 1.3-5.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181821076\">",
"    <span class=\"h3\">",
"     Recurrent thrombotic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent thrombotic events are common in APS. Most, but not all, observers have noted that an initial arterial thrombosis tends to be followed by an arterial event and that an initial venous thrombosis is usually followed by a venous event [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. In a report in which 186 recurrences occurred in 101 patients, an initial arterial thrombosis was followed by an arterial thrombosis in 93 percent, while an initial venous thrombosis was followed by a venous thrombosis in 76 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/40\">",
"     40",
"    </a>",
"    ]. The factors that determine the predilection for the venous or arterial circulation are not known.",
"   </p>",
"   <p>",
"    The recurrence rate of thrombotic events among patients with APS is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/39,41-43\">",
"     39,41-43",
"    </a>",
"    ], and the presence of aCL is a risk factor for recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/39,41-43\">",
"     39,41-43",
"    </a>",
"    ]. The largest experience comes from a prospective study of 412 patients presenting with a first episode of venous thromboembolism who were treated with six months of anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/42\">",
"     42",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of recurrence within the first six months after stopping anticoagulation was twice as high among patients with aCL compared with those without such antibodies (29 versus 14 percent). In addition, the risk of recurrence increased with the aCL titer.",
"     </li>",
"     <li>",
"      Among 34 patients with a second venous thromboembolic event and aCL, there were no recurrences during the second course of anticoagulant therapy versus 20 percent in those who were retreated for only six months.",
"     </li>",
"     <li>",
"      Four-year mortality was significantly higher in the patients with aCL (15 versus 6 percent in those without aCL).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognostic importance of aCL was noted in another cohort of 56 patients with primary APS who were followed for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/43\">",
"     43",
"    </a>",
"    ]. Fifteen patients (27 percent) had at least one recurrent event. On multivariate analysis, only an aCL level &gt;40 GPL units was an independent predictor of recurrent thromboembolic events.",
"   </p>",
"   <p>",
"    Women presenting with pregnancy loss as their only manifestation of APS are also at risk of subsequent thrombotic events, as shown in a 10-year study that followed women with pregnancy loss consistent with obstetric criteria for APS, who were without a prior history of thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/44\">",
"     44",
"    </a>",
"    ]. Women with aPL (n = 517) exhibited significant and nearly twofold increases in the risk of deep vein thrombosis (DVT), pulmonary embolus (PE), and stroke or transient ischemic attack (TIA), compared with women without evidence of thrombophilias (n = 796) (adjusted hazard ratios 1.85, 95% CI 1.50-2.28; 1.93, 95% CI 1.30-2.87; and 1.87, 95% CI 1.20-2.93, respectively), despite administration of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    to the women who presented with purely obstetric APS. The absolute risks of DVT, PE, and stroke or TIA in the patients with APS were 13.2, 3.9, and 2.9 percent, respectively. Lupus anticoagulant was a dose-dependent risk factor for unprovoked proximal and distal deep and superficial vein thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neurologic syndromes besides stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strong associations are now recognized between the presence of aPL and the occurrence of cognitive deficits",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    white matter lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/32,45\">",
"     32,45",
"    </a>",
"    ]. However, the link with APS is less strong for other neurological associations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cognitive deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable interest, and controversy, has focused on the relationship between aPL and cognitive deficits. The degree of reported cognitive deficits ranges from subtle findings to transient global amnesia to permanent and profound cognitive functioning. The cognitive deficits reported in APS are sometimes but not always associated with white matter lesions.",
"   </p>",
"   <p>",
"    Cognitive deficits were demonstrated in a study of 60 patients with primary or secondary APS who underwent comprehensive neuropsychological testing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/22\">",
"     22",
"    </a>",
"    ]. The APS patients were compared with 60 healthy controls, matched for age, sex, and education, and 25 disease controls (SLE and rheumatoid arthritis patients who did not have APS). The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cognitive deficits were significantly more frequent in the patients with APS (42 versus 18 and 16 percent of the healthy and disease controls, respectively).",
"     </li>",
"     <li>",
"      Cognitive dysfunction in the APS patients was associated with the presence of livedo reticularis on physical examination and with the finding of white matter lesions on brain MRI.",
"     </li>",
"     <li>",
"      No relationship was detected between cognitive dysfunction and previous central nervous system disease (eg, stroke).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     White matter lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system involvement in APS is associated with high-intensity lesions on MRI that are suggestive of a vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/46\">",
"     46",
"    </a>",
"    ]. These lesions may be difficult to distinguish from those in multiple sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. When present in patients with clinical or serologic features of SLE or APS, these lesions have been referred to as &ldquo;lupoid sclerosis&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33978?source=see_link&amp;anchor=H23#H23\">",
"     \"Neurologic manifestations of systemic lupus erythematosus\", section on 'Cranial neuropathies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of patients with multiple sclerosis also have aPL. However, there appears to be no correlation between these antibodies and any clinical features of multiple sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other neurological associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other neurologic disorders with which aPL have been reported include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/9,10,22,52-61\">",
"     9,10,22,52-61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Epilepsy",
"     </li>",
"     <li>",
"      Psychosis",
"     </li>",
"     <li>",
"      Chorea and hemiballismus",
"     </li>",
"     <li>",
"      Transverse myelopathy",
"     </li>",
"     <li>",
"      Sensorineural hearing loss",
"     </li>",
"     <li>",
"      Orthostatic hypotension",
"     </li>",
"     <li>",
"      Migraine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The strength of association for many of these conditions is weak.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pregnancy loss and preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of APS may be related to several types of morbidities during pregnancy. These include fetal death after 10 weeks gestation, premature birth due to severe preeclampsia or placental insufficiency, or multiple embryonic losses (&lt;10 weeks gestation). Fetal loss in patients with aPL and the approach to women with recurrent fetal loss are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26679?source=see_link\">",
"     \"Evaluation of couples with recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with preeclampsia or the HELLP Syndrome (hemolysis, elevated liver enzymes, and low platelet count in association with pregnancy), the possibility of the catastrophic APS must be considered, particularly in patients with histories of thrombosis or spontaneous abortions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Catastrophic APS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hematologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prominent hematologic manifestations of APS include thrombocytopenia, microangiopathic hemolytic anemia, and, in rare cases, bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia is among the most common clinical manifestations of APS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/10\">",
"     10",
"    </a>",
"    ]. The platelet count is usually in the range of 50,000 to",
"    <span class=\"nowrap\">",
"     140,000/microL.",
"    </span>",
"    Thrombocytopenia does not preclude the occurrence of thrombotic complications of APS.",
"   </p>",
"   <p>",
"    A review of 13 studies of 869 patients with SLE",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    SLE-like diseases) found that thrombocytopenia was more common in those with LA (55 percent) and aCL (29 percent) than in those without these antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/63\">",
"     63",
"    </a>",
"    ]. Conversely, patients with thrombocytopenia associated with autoimmune disorders frequently have aPL (eg, 70 to 82 percent of patients with SLE and thrombocytopenia and 30 to 40 percent of those with immune thrombocytopenia [ITP]) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/10,63-65\">",
"     10,63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of developing thrombotic events or fetal loss is increased in patients with ITP who have aPL. This was illustrated in a prospective study of 82 patients presenting with ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/65\">",
"     65",
"    </a>",
"    ]. The rate of thrombotic events or fetal loss at five years was approximately 60 percent in the 31 patients (38 percent) with aPL, compared with 2 to 4 percent in those who did not have aPL. Patients with ITP and the persistent presence of a LA appeared to be at highest risk; nearly half of such patients developed thrombotic events during a mean of 38 months of follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Thrombotic microangiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;aPL have been implicated in some cases of thrombotic thrombocytopenic",
"    <span class=\"nowrap\">",
"     purpura/hemolytic-uremic",
"    </span>",
"    syndrome",
"    <span class=\"nowrap\">",
"     (TTP/HUS)",
"    </span>",
"    that occur in SLE. In one report, for example, five of eight such patients had aPL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/66\">",
"     66",
"    </a>",
"    ]. In addition, some patients with primary APS develop TTP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H31#H31\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Antiphospholipid antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a review of 46 patients with thrombotic microangiopathy and aPL, the following associated clinical syndromes were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       TTP/HUS",
"      </span>",
"      in 33 percent",
"     </li>",
"     <li>",
"      Catastrophic APS in 23 percent (see",
"      <a class=\"local\" href=\"#H37\">",
"       'Catastrophic APS'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Acute renal failure in 15 percent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35287?source=see_link\">",
"       \"Antiphospholipid syndrome and the kidney\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Malignant hypertension in 13 percent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"       \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count in association with pregnancy) in 4 percent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with APS have only manifestations of hemolysis. In a series of 1000 patients with APS, hemolytic anemia was observed in 10 percent at some time during a mean of seven years of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/10\">",
"     10",
"    </a>",
"    ]. However, this cohort included patients with SLE, and the cause of the hemolysis was not stated. Both autoimmune hemolytic anemia and microangiopathic destruction of red cells may play a role in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Bleeding episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of antibodies to prothrombin should be suspected when a patient with a known LA also has a low prothrombin level and develops bleeding complications rather than thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H20#H20\">",
"     \"Acquired inhibitors of coagulation\", section on 'Prothrombin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary embolism occurs in approximately one-third of patients with APS who develop DVT. Other recognized pulmonary complications of APS include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/10,70-73\">",
"     10,70-73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary arterial thrombosis with or without thromboembolic pulmonary hypertension (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alveolar hemorrhage (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"       \"The diffuse alveolar hemorrhage syndromes\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, fibrosing alveolitis, adult respiratory distress syndrome, and nonthromboembolic pulmonary hypertension have been reported in association with aPL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. However, the relationship of these disorders to aPL is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with aPL commonly have cardiac disease, including valvular thickening, mitral valve nodules, and nonbacterial vegetations (",
"    <a class=\"graphic graphic_picture graphicRef79709 \" href=\"UTD.htm?37/6/37984\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/10,19,72,74-77\">",
"     10,19,72,74-77",
"    </a>",
"    ]. Involvement of the mitral and aortic valves can lead to valvular regurgitation and, rarely, to stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    aPL have also been incriminated in intracardiac thrombi, pericardial effusion, cardiomyopathy, emboli in those with or without infective endocarditis, premature restenosis of vein grafts for coronary bypass, and peripheral vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/10,19,74,75,78-82\">",
"     10,19,74,75,78-82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Valvular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between aPL and cardiovascular manifestations of SLE was evaluated in a group of 200 patients from an SLE registry; 21 percent had either aCL or a LA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/77\">",
"     77",
"    </a>",
"    ]. The patients with aPL had higher rates of mitral valve nodules and moderate to severe mitral regurgitation (14 versus 4 percent without aPL). Mitral valve nodules were more common in patients with high titers of IgG aPL (31 versus 4 percent without aPL). aPL were not associated with cardiac hypertrophy, systolic dysfunction, atherosclerosis, or pulmonary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Ischemic heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether an association exists between APS and an increased incidence of ischemic heart disease has been controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/35,83-85\">",
"     35,83-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a different series, aCL were present in 20 percent of patients with ischemic heart disease and no other autoimmune disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/83\">",
"       83",
"      </a>",
"      ], and antibodies to &szlig;2-GP-I were present in 30 percent of patients with unstable angina [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An association between angina pectoris with angiographically normal epicardial coronary arteries (cardiac syndrome X) and APS has been suggested [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormalities on contrast-enhanced cardiac MRI were more prevalent among patients with APS (8 of 27, 30 percent) than among healthy controls (3 of 87, 3.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/87\">",
"       87",
"      </a>",
"      ]. These observations, if confirmed, suggest that many patients with APS are at risk for CAD.",
"     </li>",
"     <li>",
"      A case-control study of 2000 patients found a substantial increase in the risk of myocardial infarction associated with the presence of IgG aCL directed against &szlig;2-GP-I (adjusted odds ratio of 1.8, 95% CI 1.2-2.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/35\">",
"       35",
"      </a>",
"      ]. As was the case for stroke risk, aCL alone, antibodies to &szlig;2-GP-I alone, and aPL of any immunoglobulin class other than IgG did not confer an increased risk of myocardial infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Spontaneous echo contrast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous echo contrast (SEC) in the left atrium, a finding that is thought to result from clumping of red blood cells in the setting of low shear stress, is a risk factor for left atrial thrombus formation and arterial embolism. SEC is present in up to 16 percent of APS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/76\">",
"     76",
"    </a>",
"    ], but its clinical significance in this setting is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link&amp;anchor=H4#H4\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\", section on 'Left atrial spontaneous echo contrast'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;aPL have been associated with many cutaneous abnormalities including splinter hemorrhages, livedo reticularis (",
"    <a class=\"graphic graphic_picture graphicRef67495 \" href=\"UTD.htm?41/27/42418\">",
"     picture 3",
"    </a>",
"    ), cutaneous necrosis and infarction, thrombophlebitis, digital gangrene, skin ulcerations, lesions resembling vasculitis (&ldquo;pseudovasculitic&rdquo; nodules, macules), and livedoid vasculopathy (atrophie blanche) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/5,10,88-90\">",
"     5,10,88-90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6103?source=see_link\">",
"     \"Livedoid vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A loss of normal elastic tissue known as anetoderma, which presents as localized areas of wrinkled or flaccid skin, has also been noted in patients with SLE and APS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/5,91\">",
"     5,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of livedo reticularis in association with stroke is known as Sneddon&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/33\">",
"     33",
"    </a>",
"    ]. In approximately 50 percent of cases, Sneddon&rsquo;s syndrome is associated with detectable aPL.",
"   </p>",
"   <p>",
"    In a series of 200 consecutive cases of patients with APS (either primary APS or APS secondary to SLE), 49 percent of patients had cutaneous findings associated with their disease. In 31 percent of cases, the cutaneous lesions were evident at presentation. The following frequency of lesions was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/89\">",
"     89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Livedo reticularis &mdash; 26 percent",
"     </li>",
"     <li>",
"      Digital necrosis &mdash; 8 percent",
"     </li>",
"     <li>",
"      Splinter hemorrhages &mdash; 5 percent",
"     </li>",
"     <li>",
"      Superficial venous thrombosis &mdash; 5 percent",
"     </li>",
"     <li>",
"      Post-phlebitic ulcers &mdash; 5 percent",
"     </li>",
"     <li>",
"      Circumscribed cutaneous necrosis &mdash; 4 percent",
"     </li>",
"     <li>",
"      Thrombocytopenic purpura &mdash; 4 percent",
"     </li>",
"     <li>",
"      Pseudovasculitis &mdash; 3 percent",
"     </li>",
"     <li>",
"      Extensive cutaneous necrosis &mdash; 2 percent",
"     </li>",
"     <li>",
"      Anetoderma &mdash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Livedo reticularis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Livedo reticularis is associated with arterial lesions and multiple thromboses in APS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/92\">",
"     92",
"    </a>",
"    ]. In the review of 200 patients, livedo reticularis was associated with cerebral or ocular ischemic events (odds ratio 10.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/89\">",
"     89",
"    </a>",
"    ]. In contrast, livedo reticularis was observed with decreased frequency in patients who experienced only venous thromboses (odds ratio 0.2).",
"   </p>",
"   <p>",
"    There is considerable ambiguity in the literature with regard to the terms &ldquo;livedo reticularis&rdquo; and &ldquo;livedo racemosa&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/93\">",
"     93",
"    </a>",
"    ]. Livedo racemosa is characterized by a violaceous net-like pattern on the skin with irregular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    broken circles; livedo reticularis is characterized by unbroken circles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/94\">",
"     94",
"    </a>",
"    ]. Livedo racemosa, named by Ehrmann in 1907 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/95\">",
"     95",
"    </a>",
"    ], is a more striking cutaneous finding than livedo reticularis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/93\">",
"     93",
"    </a>",
"    ]. In addition, livedo reticularis often occurs in physiologic settings rather than in disease states [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of differentiating between livedo racemosa and livedo reticularis was illustrated in a study of 111 patients with livedo racemosa and 32 patients with livedo reticularis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/94\">",
"     94",
"    </a>",
"    ]. The former were more likely to have biopsy-proven cutaneous vasculitis; to be younger and male; and to have arthralgia, higher levels of CRP, and antibodies to phosphatidylserine prothrombin complexes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic renal disease occurs in a minority of patients with APS. Glomerular capillaries and other renal vessels, both arteries and veins of all sizes, can be affected. The disease may be silent or may produce acute or chronic renal failure with proteinuria. A detailed discussion of kidney disease associated with aPL is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35287?source=see_link\">",
"     \"Antiphospholipid syndrome and the kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with aPL may have ischemia involving the esophagus, stomach, duodenum, jejunum, ileum, or colon resulting in gastrointestinal bleeding, abdominal pain, an acute abdomen, esophageal necrosis with perforation, or giant gastric or atypical duodenal ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/97\">",
"     97",
"    </a>",
"    ]. Splenic or pancreatic infarction may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, the liver may be involved; hepatic or portal venous thrombosis may result in the Budd-Chiari syndrome, hepatic-veno-occlusive disease, hepatic infarction, portal hypertension, and cirrhosis. [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Ocular manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amaurosis fugax, retinal venous and arterial occlusion, and anterior ischemic optic neuropathy have occurred in patients with aPL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/10,98\">",
"     10,98",
"    </a>",
"    ]. The presence of such antibodies may be a risk factor for occlusive vascular disorders of the eye. This association was illustrated in a case-control study of 68 patients with such occlusive disorders and 94 controls (45 with inflammatory eye diseases and 49 healthy subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/99\">",
"     99",
"    </a>",
"    ]. aCL or LA activity was present in 24 percent of those with occlusive vascular eye disease, compared with only 9 percent of those with inflammatory eye disease and 8 percent of healthy controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Adrenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of abdominal pain and weakness may be the result of adrenal insufficiency. Loss of adrenal function is most often due to adrenal hemorrhage and, less frequently, to bilateral adrenal infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/100\">",
"     100",
"    </a>",
"    ]. An enlarged adrenal or an adjacent mass may be apparent on a CT scan, but MRI is more effective in determining the age of adrenal hemorrhage and in differentiating bleeding from other causes of adrenal gland enlargement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Hemorrhagic infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Osteonecrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic changes in the appearance of the femoral heads of patients with primary APS have been noted on MRI. These findings have been interpreted to indicate osteonecrosis. However, of the 30 patients who were the subject of one report, none had changes on plain radiographs, and none had progressive changes on subsequent MRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/101\">",
"     101",
"    </a>",
"    ]. Thus, the true nature of the association between osteonecrosis and the presence of aPL is not clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link&amp;anchor=H5#H5\">",
"     \"Osteonecrosis (avascular necrosis of bone)\", section on 'Systemic lupus erythematosus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Catastrophic APS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small subset of patients with APS has widespread thrombotic disease with multiorgan failure, which is called &ldquo;catastrophic APS.&rdquo; Preliminary criteria proposed for classification purposes have previously been published and validated (",
"    <a class=\"graphic graphic_table graphicRef62724 \" href=\"UTD.htm?35/51/36667\">",
"     table 1",
"    </a>",
"    ). Additional diagnostic algorithms have been proposed to facilitate early recognition of catastrophic APS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/102\">",
"     102",
"    </a>",
"    ]. The important steps in the proposed algorithms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of APS",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aPL",
"     </li>",
"     <li>",
"      Three or more new organ thromboses within a week",
"     </li>",
"     <li>",
"      Biopsy confirmation of a microthrombus",
"     </li>",
"     <li>",
"      Exclusion of other causes of multiple organ thromboses or microthromboses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among 1000 patients with the APS followed for a mean of seven years, only eight (0.8 percent) developed catastrophic APS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/10\">",
"     10",
"    </a>",
"    ]. In the majority of these patients, multiorgan involvement was present at the time of diagnosis of APS.",
"   </p>",
"   <p>",
"    Patients with catastrophic APS may have laboratory features such as elevated fibrin degradation products, depressed fibrinogen levels, or elevated D-dimer concentrations that are more typically found with disseminated intravascular coagulation (DIC).",
"   </p>",
"   <p>",
"    Catastrophic APS is frequently fatal, with a reported mortality rate approaching 50 percent despite anticoagulant and immunosuppressive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/100\">",
"     100",
"    </a>",
"    ]. The treatment of the catastrophic APS is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of the antiphospholipid syndrome\", section on 'Catastrophic APS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Primary APS versus APS with SLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that the clinical manifestations of primary APS and APS associated with SLE are similar [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/103\">",
"     103",
"    </a>",
"    ]. In contrast, a subsequent study of 122 patients noted that the frequencies of arterial thrombosis, venous thrombosis, and fetal loss were greater in patients with APS and SLE than in those with primary APS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate issue regarding the relationship of APS and SLE is the frequency of evolution of APS into SLE or lupus-like disease. Three studies involving 70 to 128 patients with APS found a variable rate of development of SLE over time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      0 percent at five years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      4 percent at 6.5 years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/105\">",
"       105",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      13 percent at nine years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/106\">",
"       106",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of aPL in the serum of patients with SLE has been identified as an independent risk factor for premature death. This was illustrated in an observational study of 667 patients with SLE, 49 of whom died [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/107\">",
"     107",
"    </a>",
"    ]. There was an increased risk of premature death in patients with aPL, thrombocytopenia, and arterial occlusion. Other factors associated with premature death were the intensity of anticoagulation treatment, renal involvement, pleuritis, and disease activity.",
"   </p>",
"   <p>",
"    Although some of the risk of early death is due to the increased propensity to thromboembolic disease, in some settings, the presence of aPL may be a marker for a higher mortality rate that is not due to thrombophilia per se. As an example, in a study of 300 consecutive patients with a first ischemic stroke, stroke victims with elevated levels of aPL (IgG ACL &gt;20 units) had a higher mortality rate during approximately two years of follow-up than those with lower or absent aCL levels (33 versus 18 percent mortality, relative risk 1.94, 95% CI 1.05-3.67) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/31/23034/abstract/108\">",
"     108",
"    </a>",
"    ]. However, the increased mortality was not due to recurrent stroke but was associated with other characteristics of those with aPL, including a higher rate of malignancy and more prevalent risk factors for coronary heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=see_link\">",
"       \"Patient information: The antiphospholipid syndrome (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    The antiphospholipid syndrome (APS) is defined by two major components (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Classification criteria'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The occurrence of at least one clinical feature: vascular event or pregnancy morbidity",
"     </li>",
"     <li>",
"      The presence of at least one type of autoantibody known as an antiphospholipid antibody (aPL) on two separate occasions at least 12 weeks apart",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there are aPL-related clinical manifestations that are not part of the APS classification criteria, such as livedo reticularis, thrombocytopenia, cardiac valve disease, or aPL-nephropathy.",
"   </p>",
"   <p>",
"    APS occurs either as a primary condition or in the setting of an underlying disease, particularly systemic lupus erythematosus (SLE). (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Primary APS versus APS with SLE'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    aPL are directed against serum proteins bound to anionic phospholipids and may be detected by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lupus anticoagulant tests",
"     </li>",
"     <li>",
"      Anticardiolipin antibody ELISA",
"     </li>",
"     <li>",
"      Anti-&szlig;2 glycoprotein-I ELISA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H2\">",
"     'The antibodies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thromboses are the most common clinical manifestation of APS. The most common sites for venous thrombosis are deep venous thrombosis in the veins of the calf; the renal veins; the hepatic, axillary, subclavian, and retinal veins; the cerebral sinuses; and the venae cavae. Pulmonary emboli may result from these thromboses. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Thrombosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most common site of arterial thrombosis in APS is the brain. Ischemic stroke may also result from arterial thromboembolism. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Stroke'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Aside from strokes, a variety of other neurological syndromes have been associated with APS, including cognitive deficits and white matter lesions. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Neurologic syndromes besides stroke'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pregnancy manifestations of APS include fetal death after 10 weeks gestation, premature births due to severe preeclampsia or placental insufficiency, or multiple embryonic losses (&lt;10 weeks gestation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26679?source=see_link\">",
"     \"Evaluation of couples with recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In APS-associated thrombocytopenia, the platelet count is usually not severely low but rather in the range of 50,000 to",
"    <span class=\"nowrap\">",
"     140,000/microL.",
"    </span>",
"    Thrombosis can occur in APS even in the presence of thrombocytopenia. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Thrombocytopenia'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/1\">",
"      Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations--a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/2\">",
"      Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007; 5:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/3\">",
"      Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007; 5:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/4\">",
"      Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/5\">",
"      Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/6\">",
"      Reber G, Tincani A, Sanmarco M, et al. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/7\">",
"      Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/8\">",
"      Wisl&oslash;ff F, Jacobsen EM, Liest&oslash;l S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2002; 108:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/9\">",
"      Avcin T, Cimaz R, Meroni PL. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus 2002; 11:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/10\">",
"      Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/11\">",
"      Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/12\">",
"      Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other \"antiphospholipid\" autoantibodies. Blood 1994; 84:2854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/13\">",
"      Santoro SA. Antiphospholipid antibodies and thrombotic predisposition: underlying pathogenetic mechanisms. Blood 1994; 83:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/14\">",
"      Asherson RA, Khamashta MA, Ordi-Ros J, et al. The \"primary\" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/15\">",
"      Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/16\">",
"      Kincaid-Smith P, Fairley KF, Kloss M. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med 1988; 68:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/17\">",
"      D'Agati V, Kunis C, Williams G, Appel GB. Anti-cardiolipin antibody and renal disease: a report three cases. J Am Soc Nephrol 1990; 1:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/18\">",
"      Mandreoli M, Zucchelli P. Renal vascular disease in patients with primary antiphospholipid antibodies. Nephrol Dial Transplant 1993; 8:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/19\">",
"      Goodnight SH. Antiphospholipid antibodies and thrombosis. Curr Opin Hematol 1994; 1:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/20\">",
"      Asherson RA, Liot&eacute; F, Page B, et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1993; 20:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/21\">",
"      Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am 1997; 81:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/22\">",
"      Tektonidou MG, Varsou N, Kotoulas G, et al. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med 2006; 166:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/23\">",
"      Sanna G, Bertolaccini ML, Khamashta MA. Unusual clinical manifestations of the antiphospholipid syndrome. Current Rheumatology Reviews 2006; 2:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/24\">",
"      Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/25\">",
"      Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/26\">",
"      Gromnica-Ihle E, Sch&ouml;ssler W. Antiphospholipid syndrome. Int Arch Allergy Immunol 2000; 123:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/27\">",
"      Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/28\">",
"      Harris EN, Chan JK, Asherson RA, et al. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986; 146:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/29\">",
"      Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/30\">",
"      Runchey SS, Folsom AR, Tsai MY, et al. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002; 119:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/31\">",
"      Wahl DG, Guillemin F, de Maistre E, et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/32\">",
"      Muscal E, Brey RL. Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons. Curr Rheumatol Rep 2008; 10:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/33\">",
"      SNEDDON IB. CEREBRO-VASCULAR LESIONS AND LIVEDO RETICULARIS. Br J Dermatol 1965; 77:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/34\">",
"      Munts AG, van Genderen PJ, Dippel DW, et al. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 1998; 245:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/35\">",
"      Brey RL, Abbott RD, Curb JD, et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke 2001; 32:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/36\">",
"      Brey RL, Stallworth CL, McGlasson DL, et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002; 33:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/37\">",
"      Janardhan V, Wolf PA, Kase CS, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 2004; 35:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/38\">",
"      Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/39\">",
"      Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/40\">",
"      Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/41\">",
"      Levine SR, Brey RL. Neurological aspects of antiphospholipid antibody syndrome. Lupus 1996; 5:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/42\">",
"      Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/43\">",
"      Turiel M, Sarzi-Puttini P, Peretti R, et al. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke 2005; 36:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/44\">",
"      Gris JC, Bouvier S, Molinari N, et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012; 119:2624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/45\">",
"      Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/46\">",
"      Toubi E, Khamashta MA, Panarra A, Hughes GR. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995; 99:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/47\">",
"      Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000; 79:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/48\">",
"      Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry 2006; 77:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/49\">",
"      Harris EN, Gharavi AE, Mackworth-Young CG, et al. Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies. Ann Rheum Dis 1985; 44:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/50\">",
"      Scott TF, Hess D, Brillman J. Antiphospholipid antibody syndrome mimicking multiple sclerosis clinically and by magnetic resonance imaging. Arch Intern Med 1994; 154:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/51\">",
"      Roussel V, Yi F, Jauberteau MO, et al. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun 2000; 14:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/52\">",
"      Shoenfeld Y, Lev S, Blatt I, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004; 31:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/53\">",
"      Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003; 42:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/54\">",
"      Asherson RA, Mercey D, Phillips G, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987; 46:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/55\">",
"      Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer &gt; 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997; 28:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/56\">",
"      Herranz MT, Rivier G, Khamashta MA, et al. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/57\">",
"      Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997; 76:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/58\">",
"      Verrot D, San-Marco M, Dravet C, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/59\">",
"      Kandiah DA, Sali A, Sheng Y, et al. Current insights into the \"antiphospholipid\" syndrome: clinical, immunological, and molecular aspects. Adv Immunol 1998; 70:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/60\">",
"      Mouadeb DA, Ruckenstein MJ. Antiphospholipid inner ear syndrome. Laryngoscope 2005; 115:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/61\">",
"      Chapman J, Rand JH, Brey RL, et al. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003; 12:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/62\">",
"      G&oacute;mez-Puerta JA, Cervera R, Espinosa G, et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 2007; 66:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/63\">",
"      McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/64\">",
"      Harris EN, Gharavi AE, Hegde U, et al. Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. Br J Haematol 1985; 59:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/65\">",
"      Diz-K&uuml;&ccedil;&uuml;kkaya R, Hacihanefio��lu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/66\">",
"      Nesher G, Hanna VE, Moore TL, et al. Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994; 24:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/67\">",
"      Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004; 63:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/68\">",
"      Vivaldi P, Rossetti G, Galli M, Finazzi G. Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica 1997; 82:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/69\">",
"      Erkan D, Bateman H, Lockshin MD. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Lupus 1999; 8:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/70\">",
"      Espinosa G, Cervera R, Font J, Asherson RA. The lung in the antiphospholipid syndrome. Ann Rheum Dis 2002; 61:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/71\">",
"      Asherson RA, Higenbottam TW, Dinh Xuan AT, et al. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990; 17:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/72\">",
"      Jouhikainen T, Pohjola-Sintonen S, Stephansson E. Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus 1994; 3:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/73\">",
"      Deane KD, West SG. Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review. Semin Arthritis Rheum 2005; 35:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/74\">",
"      Esp&iacute;nola-Zavaleta N, Vargas-Barr&oacute;n J, Colmenares-Galvis T, et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J 1999; 137:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/75\">",
"      Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996; 93:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/76\">",
"      Turiel M, Sarzi-Puttini P, Peretti R, et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol 2005; 96:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/77\">",
"      Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 2006; 54:3918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/78\">",
"      Morton KE, Gavaghan TP, Krilis SA, et al. Coronary artery bypass graft failure--an autoimmune phenomenon? Lancet 1986; 2:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/79\">",
"      Nityanand S, Bergmark C, de Faire U, et al. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med 1995; 238:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/80\">",
"      Kupferwasser LI, Hafner G, Mohr-Kahaly S, et al. The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. J Am Coll Cardiol 1999; 33:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/81\">",
"      Puisieux F, de Groote P, Masy E, et al. Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease. Am J Med 2000; 109:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/82\">",
"      Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005; 64:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/83\">",
"      Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study. Am J Med 1996; 101:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/84\">",
"      Raghavan C, Ditchfield J, Taylor RJ, et al. Influence of anticardiolipin antibodies on immediate patient outcome after myocardial infarction. J Clin Pathol 1993; 46:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/85\">",
"      Farsi A, Domeneghetti MP, Fedi S, et al. High prevalence of anti-beta2 glycoprotein I antibodies in patients with ischemic heart disease. Autoimmunity 1999; 30:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/86\">",
"      Sangle SR, D'Cruz DP. Syndrome X (angina pectoris with normal coronary arteries) and myocardial infarction in patients with anti-phospholipid (Hughes) syndrome. Lupus 2008; 17:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/87\">",
"      Sacr&eacute; K, Brihaye B, Hyafil F, et al. Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis Rheum 2010; 62:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/88\">",
"      Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol 1997; 36:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/89\">",
"      Franc&egrave;s C, Niang S, Laffitte E, et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 2005; 52:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/90\">",
"      Hairston BR, Davis MD, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol 2006; 142:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/91\">",
"      Marzano A, Vanotti M, Alessi E. Anetodermic lupus panniculitis and antiphospholipid antibodies: report of three cases. Acta Derm Venereol 2004; 84:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/92\">",
"      Toubi E, Krause I, Fraser A, et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005; 23:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/93\">",
"      Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol 2006; 33:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/94\">",
"      Kawakami T, Yamazaki M, Mizoguchi M, Soma Y. Differences in anti-phosphatidylserine-prothrombin complex antibodies and cutaneous vasculitis between regular livedo reticularis and livedo racemosa. Rheumatology (Oxford) 2009; 48:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/95\">",
"      Ehrmann S. Ein Gefaessprozess Bei Lues. Wien Med Wochenschr 1907; 57:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/96\">",
"      Gibbs MB, English JC 3rd, Zirwas MJ. Livedo reticularis: an update. J Am Acad Dermatol 2005; 52:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/97\">",
"      Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology (Oxford) 2007; 46:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/98\">",
"      Miserocchi E, Baltatzis S, Foster CS. Ocular features associated with anticardiolipin antibodies: a descriptive study. Am J Ophthalmol 2001; 131:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/99\">",
"      Carbone J, S&aacute;nchez-Ram&oacute;n S, Cobo-Soriano R, et al. Antiphospholipid antibodies: a risk factor for occlusive retinal vascular disorders. Comparison with ocular inflammatory diseases. J Rheumatol 2001; 28:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/100\">",
"      Espinosa G, Santos E, Cervera R, et al. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore) 2003; 82:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/101\">",
"      Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, et al. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum 2003; 48:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/102\">",
"      Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010; 10:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/103\">",
"      Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994; 96:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/104\">",
"      Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; 36:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/105\">",
"      Mujic F, Cuadrado MJ, Lloyd M, et al. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. J Rheumatol 1995; 22:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/106\">",
"      G&oacute;mez-Puerta JA, Mart&iacute;n H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005; 84:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/107\">",
"      Drenkard C, Villa AR, Alarc&oacute;n-Segovia D, P&eacute;rez-V&aacute;zquez ME. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994; 21:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/31/23034/abstract/108\">",
"      Tanne D, D'Olhaberriague L, Trivedi AM, et al. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology 2002; 21:93.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4667 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23034=[""].join("\n");
var outline_f22_31_23034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H160817402\">",
"      aCL and &szlig;2-GP-I assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H160817409\">",
"      Lupus anticoagulant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OTHER ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLASSIFICATION CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Initial site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Deep venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181821076\">",
"      - Recurrent thrombotic events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neurologic syndromes besides stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cognitive deficits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - White matter lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other neurological associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pregnancy loss and preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hematologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Thrombotic microangiopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Bleeding episodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Valvular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Spontaneous echo contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Livedo reticularis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Ocular manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Adrenal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Osteonecrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Catastrophic APS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Primary APS versus APS with SLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/4667\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4667|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/63/25590\" title=\"picture 1\">",
"      Thrombotic microangiopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/6/37984\" title=\"picture 2\">",
"      Verrucous endocarditis in SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/27/42418\" title=\"picture 3\">",
"      Livedo reticularis in lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4667|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/51/36667\" title=\"table 1\">",
"      Catastrophic APS criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35287?source=related_link\">",
"      Antiphospholipid syndrome and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=related_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26679?source=related_link\">",
"      Evaluation of couples with recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6103?source=related_link\">",
"      Livedoid vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33978?source=related_link\">",
"      Neurologic manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=related_link\">",
"      Patient information: The antiphospholipid syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_31_23035="Colorado guidelines for concussion management";
var content_f22_31_23035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Colorado guideline for concussion management",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Presentation",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         1. Confusion without amnesia",
"        </p>",
"        <p>",
"         2. No loss of consciousness",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         1. Confusion with amnesia",
"        </p>",
"        <p>",
"         2. No loss of consciousness",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         1. Loss of consciousness of any duration",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Management",
"       </td>",
"       <td>",
"        Evaluate athlete immediately and every 5 minutes. Athlete may",
"return to play if amnesia or symptoms do not appear for 20 minutes.",
"       </td>",
"       <td>",
"        Examine the athlete the next day.  Athlete may return to play after one week if asymptomatic during that time.",
"       </td>",
"       <td>",
"        Transport athlete to the emergency department; athlete may return",
"to play if asymptomatic for 2 weeks and cleared by neurologist or",
"neurosurgeon.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Colorado Medical Society, Report of the Sports Medicine Committee, 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23035=[""].join("\n");
var outline_f22_31_23035=null;
var title_f22_31_23036="Histopathology of cutaneous blisters";
var content_f22_31_23036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histopathological sites of blister formation in blistering disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intracorneal/subcorneal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intraepidermal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suprabasilar",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subepidermal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Staphylococcal scalded skin syndrome",
"        </p>",
"        <p>",
"         Miliaria crystallina",
"        </p>",
"        <p>",
"         Bullous impetigo",
"        </p>",
"        <p>",
"         Pemphigus foliaceus",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Varicella zoster virus infection*",
"        </p>",
"        <p>",
"         Herpes simplex virus infection*",
"        </p>",
"        <p>",
"         Epidermolysis bullosa simplex",
"        </p>",
"        <p>",
"         Acute palmoplantar (dyshidrotic) eczema",
"        </p>",
"        <p>",
"         Autoeczematization (id) reaction",
"        </p>",
"        <p>",
"         Friction blister",
"        </p>",
"        <p>",
"         Polymorphous light eruption",
"        </p>",
"        <p>",
"         Contact dermatitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Paraneoplastic pemphigus*",
"        </p>",
"        <p>",
"         Pemphigus vulgaris",
"        </p>",
"        <p>",
"         Transient acantholytic dermatosis",
"        </p>",
"        <p>",
"         Hailey-Hailey disease",
"        </p>",
"        <p>",
"         Darier's disease",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Stevens-Johnson syndrome",
"        </p>",
"        <p>",
"         Sweet's syndrome",
"        </p>",
"        <p>",
"         Bullous systemic lupus erythematosus",
"        </p>",
"        <p>",
"         Bullous pemphigoid",
"        </p>",
"        <p>",
"         Pemphigus gestationis",
"        </p>",
"        <p>",
"         Linear IgA bullous dermatosis",
"        </p>",
"        <p>",
"         Dermatitis herpetiformis",
"        </p>",
"        <p>",
"         Junctional epidermolysis bullosa",
"        </p>",
"        <p>",
"         Dystrophic epidermolysis bullosa",
"        </p>",
"        <p>",
"         Epidermolysis bullosa acquisita",
"        </p>",
"        <p>",
"         Coma blister",
"        </p>",
"        <p>",
"         Bullous disease of diabetes",
"        </p>",
"        <p>",
"         Bullous leukocytoclastic vasculitis",
"        </p>",
"        <p>",
"         Erythema multiforme",
"        </p>",
"        <p>",
"         Porphyria cutanea tarda",
"        </p>",
"        <p>",
"         Phototoxic reaction",
"        </p>",
"        <p>",
"         Arthropod bite",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Fixed drug eruption",
"        </p>",
"        <p>",
"         Bullous pyoderma gangrenosum",
"        </p>",
"        <p>",
"         Mucous membrane pemphigoid",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * May also be subepidermal.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      May also be intraepidermal.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23036=[""].join("\n");
var outline_f22_31_23036=null;
var title_f22_31_23037="Porphyria oxidation";
var content_f22_31_23037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postulated mechanism whereby uroporphrinogen is oxidized to uroporphyrin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 375px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Postulated mechanism for UROD inhibition in porphyria cutanea tarda.&nbsp;Uroporphrinogen is oxidized by cytochrome P450 enzymes (especially CYP1A2) to uroporphyrin, which accumulates in the liver, and is converted, in the presence of iron,&nbsp;to uroporphomethene, a specific UROD inhibitor.",
"    <div class=\"footnotes\">",
"     ALAS1: housekeeping form of ALA synthase; UROD: uroporphyrinogen decarboxylase; CYP1A2: cytochrome P450 1A2.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anderson, KE. Porphyria cutanea tarda: a possible role for ascorbic acid. Hepatology 2007; 45:6. Copyright &copy; 2007 John Wiley &amp; Sons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23037=[""].join("\n");
var outline_f22_31_23037=null;
var title_f22_31_23038="Serology acute to chronic HCV";
var content_f22_31_23038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serologic pattern of acute HCV infection with progression of chronic infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 325px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Figure provided by the Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23038=[""].join("\n");
var outline_f22_31_23038=null;
var title_f22_31_23039="FISH";
var content_f22_31_23039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Algorithm for FISH in assessment of HER2 status",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 472px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * HER2, human epidermal growth factor receptor 2.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolff AC, Hammond EH, Schwartz JN. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Onc 2007; 25:1. Copyright &copy; 2007 the American Society of Clinical Oncology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_31_23039=[""].join("\n");
var outline_f22_31_23039=null;
